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Part A is a research protocol which describes the background and proposed methodology of 
this systematic review. This section contains the details of quantitative and qualitative 
methods to be used when analysing rheumatic heart disease (RHD) prevention and care 
programmes. 
Part B is a literature review which expands on the protocol. An in-depth explanation of the 
disease process is presented in order to understand the multiple opportunities for 
preventing RHD and its precursors. The importance of this research then is highlighted by 
contextualising RHD programmes within the health system and integrated care. 
Part C presents the research as a journal manuscript according the BMJ’s instructions for 
authors. The manuscript includes a brief introduction to the research followed by a 
summary of the methods and presentation of the results which are then discussed. 
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PART A: PROTOCOL 





ARF Acute Rheumatic Fever 
BPG Benzathine Penicillin G 
GAS Group A Streptococcus 
HICs High-income countries 
INR International Normalised Ratio 
LMICs Low and Middle Income Countries 
RADT Rapid Antigen Detection Test 
RHD Rheumatic Heart Disease 






Disability-adjusted life years A measure of overall disease burden, expressed as the numberof 
years lost due to ill-health, disability or early death. 
 
Gram-positive bacteria Bacteria which appear violet following a gram stain as a direct 
result their cell wall characteristics. 
Pathogenesis The manner of development of a disease. 
 
Subclinical Relating to or denoting a disease which is not severe enough to 
present definite or readily observable symptoms. 
Aetiology The cause or set of causes or manner of causation of a disease or 
condition. 
Endemic Regularly found among particular people or in a certain area. 
Integration The extent, pattern, and rate of adoption and eventual assimilation 






Rheumatic heart disease (RHD) is a chronic cardiovascular condition which affects more 
than 30 million individuals worldwide and is responsible for about 300,000 deaths annually, 
therefore significantly contributing to global disability and mortality rates.[1] While the 
burden of RHD has mostly receded in high-income countries due to improved living 
conditions and advanced medical care, it remains a public health problem in under- 
resourced settings. Prevention and treatment of RHD has been a challenge partly due to the 
aetiology of this condition, which has its roots in infectious disease and an autoimmune 
response. 
RHD is a condition which typically develops following a single severe episode or multiple 
episodes of acute rheumatic fever (ARF), an abnormal autoimmune response to untreated 
Group A streptococcus (GAS) infection.[2] Children and young adults living in poverty- 
stricken, overcrowded, areas are particularly susceptible to GAS infection since this type of 
environment facilitates the spread of the infectious agent.[3] Among those who do not seek 
treatment for their sore throat, 0.3-3% will develop ARF and will need to be hospitalised to 
treat the array of signs and symptoms.[4] Poorly managed ARF can lead to RHD and 
irreversible damage to the heart valves for which cardiac surgery is required.[4] 
Unfortunately, barriers to such surgery results in premature deaths, the majority of which, 
occur before the age of 25 years.[2] With an estimated 10 million disability-adjusted life 
years lost due to RHD globally, the economic effects are felt at both the individual and 
national levels.[1] 
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1.1 Health system considerations 
 
 
Historically, disease control programmes have been delivered in a targeted, or vertical, 
manner which is currently viewed as unsustainable from a health systems perspective. 
However, very little evidence exists to guide the successful development of RHD 
programmes which are more integrated, or horizontal, for typically resource-constrained, 
endemic countries. 
There are multiple opportunities to intervene along the GAS to RHD pathway which can be 
at the primordial, primary, secondary or tertiary level.[4] Primordial prevention includes 
improved living conditions and access to health care in order to limit the exposure of at-risk 
individuals to GAS. Reduced incidence of ARF and RHD in developed countries has been 
attributed to improved living conditions, with many low- and middle-income countries 
(LMICs) falling behind.[5,6] Primary prevention includes the treatment of GAS infection with 
benzathine penicillin G (BPG) to mitigate the risk of ARF.[7] Patients with ARF are prescribed 
a regular dose of BPG as a secondary prevention measure against recurrences and 
development of RHD. Registers for patients with ARF and RHD are also advantageous for 
this level of prevention to monitor treatment adherence and patterns of the disease.[8] At 
the tertiary level, once RHD becomes symptomatic, surgery to repair or replace the 
damaged heart valves along with long-term medical management is required for survival. 
Vertical programmes are often targeted to a particular population or service which may 
incorporate dedicated health care professionals with specialised training at particular 
facilities, such as tuberculosis clinics.[8,9] These stand-alone programmes have been 
effective, particularly for infectious diseases, in middle-income regions such as Latin 
America and North Africa.[9] In contrast, a horizontal (herein referred to as integrated) 
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approach, incorporates elements of disease control into health systems and are viewed 
as health systems strengthening interventions.[8] Such programmes are usually linked 
to other services and are more widely available, providing a more holistic approach to 
health.[9] Funding is another distinguishing element, as vertical programmes tend to be 
donor funded or have dedicated, rigid, budgets while integrated programmes flow from 
existing health care funds.[9] 
There has been a longstanding debate about which approach is superior for disease 
interventions, however a polarized distinction such as this is too simplistic for the reality of 
health care delivery. A diagonal approach incorporating elements of both vertical and 
integrated programmes would be well suited to tackling RHD since diagonal programmes 
are designed to strengthen primary health care while performing disease-specific 
activities.[8] 
 
1.2 Importance of this review 
 
 
Most current interventions are integrated to some degree according to health system 
functions; the efficacy of more- or less- integrated programmes are often comparable, 
despite being context dependent.[10] When thinking about the most suitable intervention 
for RHD care, one needs to carefully consider the characteristics of the intervention as well 
as the nature of the health system. Efforts to scale up RHD prevention and care has been 
most frequently targeted, however taking a broad view of the whole system is critical for 
health system planning in low-income regions with scarce resources and less robust health 
systems. 
RHD has recently attracted global attention for being a preventable disease, to which the 
World Heart Federation has responded by setting a goal to achieve a 25% reduction in 
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premature deaths from ARF and RHD among individuals younger than 25 years of age, by 
the year 2025.[11] In order to achieve this, evidence-based prevention and treatment 
services require scaling up in the countries and regions which are still heavily burdened by 
RHD. 
Atun and colleagues present a conceptual framework for analysing the extent and nature of 
programme integration.[12] Briefly, the six key functions comprise (i) stewardship and 
governance, (ii) financing, (iii) planning, (iv) service delivery, (v) monitoring and evaluation, 
and (vi) demand generation. By combining this framework with a results chain, the 
effectiveness of programme integration can be inferred. 
This review will provide evidence on the effectiveness of integrating RHD-related services 
into existing health systems, with the intention of offering technical assistance to heavily 





To assess integrated programmes targeting RHD prevention and control in order to evaluate 
the effectiveness of the extent and nature of integration within the relevant health systems. 
 
3. REVIEW QUESTION 
 
 
Are RHD prevention and control programmes more or less successful based on the extent 





This protocol has been prepared according to the Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines.[13] 
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4.1 Eligibility Criteria for this Review 
 
 
4.1.1 Types of Studies 
 
A combination of analytical and descriptive studies will be considered for this review. These 
include randomised controlled trials (RCTs) and controlled clinical trials (CCTs), quasi- 
experimental, controlled before-and-after studies (CBAs), interrupted time series designs 
(ITS), cross-sectional studies. “Opinion pieces”, narrative reviews, and letters to the editor 
will not be included. 
4.1.2 Types of Participants 
 
Populations at risk of group A streptococcus infection, rheumatic fever, and/or rheumatic 
heart disease. 
4.1.3 Types of Interventions 
 
Disease prevention or control programmes, defined as a coherent and intentional effort to 
expand health services to the population.[12] We will use commonly agreed-upon 
classifications for RHD-related services: primary prevention, secondary prevention, and 
advanced medical or surgical care. We will focus on the changes in health service delivery 
brought about by the programme and the downstream impact on intermediate and final 
health outcomes. 
4.1.4 Types of Outcome Measures 
Primary outcomes: 
I. Programme characteristics will include: the programme start year, location(s), duration, 
area of emphasis (services delivered: primary, secondary, tertiary), and inputs. 
II. Programme integration: we will make use of a framework developed by Atun and 
colleagues to determine the extent of integration into the existing healthsystem.[13] 
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Integration will be defined as “the extent, pattern, and rate of adoption and eventual 
assimilation of health interventions into each of the critical functions of a health 
system”.[13] Six critical health system functions are outlined as: stewardship and 
governance, financing, planning, service delivery, monitoring and evaluation, and 
demand generation.[13] In a subsequent review by the same authors, this framework 
was used to illustrate its use in evaluating the extent of integration for programmes 
addressing several different health outcomes.[10] 
Secondary outcome: 
 
III. Programme results: A ‘results chain’ framework (Figure 1) will be used to identify the 
effects of various programmes.[15] This is a commonly used tool for evaluating the 
impact of health programmes. Specifically, the results chain consists of inputs (such as 
human and physical resources), which produce outputs (such as the volume and scope 
of services produced), which lead to outcomes (such as changes in behaviours or 
physiologic indicators of risk), which lead to final impacts (such as reductions in disease- 


















Figure 1: The results chain framework. 
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4.1.5 Exclusion Criteria 
 
Studies will be excluded should they be published prior to January 1990 or after December 
2017, if they do not correspond to the aforementioned study designs, or if they do not 
display a clear effort to expand health services to people at risk for GAS, ARF, and or RHD. 
Studies with insufficient information on programme characteristics will be excluded, as well 
as studies reporting on fewer than four of the 6 key functions of the health system. Further 
details on the eligibility criteria are displayed in Table 1. 
Table 1: Eligibility criteria for this review 
 
 Inclusion Exclusion 
Study Designs RCTS, CCTs, CBAs, ITS, quasi- Opinion pieces, narrative 
 experimental, cross-sectional. reviews, letters to the editor. 
Study Intervention and A programme showing an The intervention is not a 
Population intentional effort to expand health service, and the target 
 health services to the population population does not include 
 at risk for GAS, ARF, and or RHD. those at risk for GAS, ARF, or 
  RHD. 
Programme Characteristics The start year and duration, the Absence of any programme 
 country or region, and the type of characteristics. 
 service delivered (primary,  
 secondary, tertiary).  
Programme Integration Information on 4 or more of the 6 Information on fewer than 4 of 
 critical health system functions. the critical health system 
  functions. 
RCT, randomized controlled trial; CCT, controlled clinical trial; ITS, interrupted time series; GAS, 
group A streptococcus; ARF, acute rheumatic fever; RHD, rheumatic heart disease. 
 
 
4.2 Search Methods for the Identification of Studies 
 
 
Electronic databases to be searched include PubMed, Cochrane Central Register of 
Controlled Trials, Scopus, Web of Science, Africa Wide and CINAHL. Google Scholar and 
Global Index Medicus (which includes Latin America and the Caribbean database LILACS as 
well as World Health Organisation Library Information System WHOLIS) will be searched for 
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grey material. The search will include Medical Subject Headings (MeSh) and free term text 
items, published in English from the year 1990 onwards (Table 2). These restrictions have 
been chosen since we seek contemporary prevention and treatment programmes with 
limited time and resources. The reference lists of included papers will be hand searched for 
relevant studies. Published and unpublished data will be sourced by contacting authors as 
well as abstracts from the latest by screening abstracts from the latest relevant conferences. 
 
Table 2: Terms used in searching the databases (full search strategy available in Appendix 2). 
Subject Key search terms 











Delivery of Health Care, Integrated [MeSH] 
Preventative health services [MeSH] 









Group A strep* 
Rheumatic* 
Rheumatic heart disease[MeSh] 
Rheumatic heart disease 




4.3 Selection of Studies for Inclusion 
 
 
Two reviewer authors will independently evaluate the titles and abstracts of the search 
results and decide which papers to include. Clear reasons for exclusion will be documented. 
Any discrepancies will be discussed and where consensus cannot be reached, resolved with 
10  
a third author. The full-text of the articles finalised for inclusion will be retrieved and saved 
in Mendeley reference manager for further analysis. A flowchart will be presented to 
summarize the search process and selection of studies for this review, as per the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
 
5. DATA EXTRACTION AND MANAGEMENT 
 
 
Two reviewer authors will independently extract data using the predesigned data extraction 
form, which will be piloted beforehand with 5 studies to improve its validity (Appendix 3). 
Data extraction discrepancies will be ameliorated through discussion and where 
contradictions still remain, a third reviewer will be consulted. Extracted data will include 
details pertaining to the author, study design, duration and setting, and information for risk 
of bias assessment. We will extract a variety of qualitative and quantitative data related to 
our primary and secondary outcomes. Data will be extracted in accordance with our 
conceptual frameworks – health system key functions, type of services delivered, and 
results chain. Certain programme results data may not be reported, such as outcomes or 
impacts. In such cases, this will be noted as unreported during data extraction. Data will be 
analysed using Review Manager 5.3 (RevMan5) software. 
Efforts will be made to contact corresponding authors to source relevant information and 
clarity regarding missing data. However, if the corresponding authors fail to respond within 
one week, the other authors(s) will be contacted. The number of studies which do not 
include data pertaining to our primary and secondary will be noted. Ongoing studies will be 
classified as such. 
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6. DATA SYNTHESIS AND MANAGEMENT 
 
 
This review will synthesise study data using qualitative and quantitative approaches. We will 
transform programme characteristics into descriptive statistics, such as the proportion of 
studies focusing on primary prevention. We will create a series of data display matrices, one 
for each type of clinical service delivered; namely, primary, secondary, or tertiary levels of 
prevention, or combinations thereof. The matrices will present qualitative and quantitative 
data along the results chain (columns) for each study (rows) that provide data on the 
respective programmes. Where appropriate, we will conduct meta-analyses on the change 
of effect at different points along the results chain, focusing on outcomes (i.e. intermediate 
clinical outcomes such as the detection of new RHD cases) and impact on population 
health (i.e. disease incidence, disability, and mortality rates). Care will be taken to pool 
results only from programmes that have similar models of care delivery; otherwise, we will 
provide a narrative review of programme outcomes. 
Outcome data of included studies will be expressed as a risk ratio with corresponding 95% 
confidence interval for dichotomous data, or mean difference and standard deviation for 
continuous data. Where outcomes are measured using different scales, the standardised 
mean difference will be reported. A random effects meta-analysis will be performed 
according to the Mantel-Haenszel method in the absence of statistical heterogeneity, 
methodological difference or high risk of bias. Should the included studies be of substantial 
heterogeneity and where statistical pooling is not possible, results will be presented in a 
narrative format, including suitable tables and figures. 
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Heterogeneity will be evaluated by examining population characteristics, approaches to 
delivery of interventions, and differences in definitions or measurement of study outcomes. 
Heterogeneity of the programme effects across studies will be assessed visually by analysing 
the forest plot, the chi-square test having a 10% level of significance and using the I2 statistic 
with cut-offs of 25%, 50% and 75% representing low, medium, and high heterogeneity, 
respectively. 
Our second primary objective, to assess the extent of programme integration into existing 
health systems, will be represented in the data display matrices using an ordinal scale. If the 
number of similar studies is sufficient to conduct meta-analyses, we will attempt to identify 
the influence of programme integration on study outcomes by using either subgroup 
analysis or random-effects meta-regression with our integration score included as a 
covariate. Again if data are limited or too heterogeneous to pool, we will summarise our 
findings in a narrative format. 
 
7. RISK OF BIAS AND QUALITY APPRAISAL 
 
 
The Critical Appraisal Skills Programme (CASP) checklist will be used to assess the risk of bias 
of experimental and observational studies included in this review. Information will be 
gathered on randomization sequence generation, allocation concealment, masking of study 
participants and personnel, completeness of outcome data, selective outcome reporting and 
any other sources of bias. The risk of bias assessment will be accompanied by a summary of 
the reasoning behind the decision. Each included study will be labelled as having low, 
unclear, or high risk of bias and will be presented in a figure. Any discrepancies of bias 
assessment will be resolved through discussion or subsequent consultation with a third 
author. 
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In order to minimise publication biases, this study will employ strategies to search for, and 
include unpublished studies such as those found in grey literature. A funnel plot will be used 
to assess the risk of publication bias which will be critically examined for asymmetry both 
visually and through the use of formal tests. 
Notably, we anticipate finding a variety of descriptive, non-experimental studies. We will 
extract data relevant to our primary and secondary outcomes above but not attempt to 
quantify meta-bias in this subset of studies. 
The quality of evidence will be assessed using The Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) approach. Evidence will be graded as 











No formal ethical review is required due to the nature of the systematic review which draws 





This review will provide evidence regarding efficient models of care and best practice for 
RHD programmes. A robust analysis of the purpose, extent, and nature of integration for 
programmes and services will be of interest to decision makers in resource-constrained 
settings as well as those in more developed regions wishing to scale up RHD-related 
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activities. This review will initiate the necessary empirical research agenda that will involve 
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Rheumatic heart disease (RHD) is a preventable chronic cardiovascular condition which 
affects more than 30 million individuals worldwide and is responsible for about 300,000 
deaths annually.[1] Deaths due to RHD are most prevalent among children and young adults 
in resource-constrained settings and significantly contribute to global disability and 
mortality rates.[1] RHD may develop following a single severe episode or multiple episodes 
of acute rheumatic fever (ARF), an abnormal autoimmune response to untreated Group A 
streptococcus (GAS) infection.[2] 
Prevention of RHD can be achieved through primary prevention of the initial GAS infection 
or by controlling recurrent attacks of ARF, known as secondary prevention. Intentional 
efforts to address RHD date back to the 1950s, but appear to have tapered out as improved 
living conditions and access to penicillin-based treatment largely reduced the burden of RHD 
in high-income countries (HICs).[3,4] Unfortunately, endemic patterns of RHD remain in low- 
and middle-income countries (LMICs) and among vulnerable indigenous populations of 
certain wealthy countries.[1] 
In recent years RHD has regained global attention for being a preventable disease, to which 
the World Heart Federation has responded by setting the goal of a 25% reduction in 
premature deaths from ARF and RHD among individuals younger than 25 years of age, by 
the year 2025.[5,6] More recently, the Resolution on Rheumatic Fever and Rheumatic Heart 
Disease was approved during the 71st World Health Assembly, and in so doing member 
states are now accountable to show progress toward eradication of the disease.[7] The 
Addis Ababa Communique followed by the Cairo Accord outline key actionable strategies 
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eradicate RHD, such as establishing registers, decentralising diagnostic services for ARF and 
RHD, ensuring a reliable supply of quality benzathine penicillin, implementing a multi- 
sectoral national RHD programme, and improving access to cardiac surgical services. [8,9] 
In order to achieve the desired progress, evidence-based prevention and treatment services 
require scaling up in the countries and regions which are still heavily burdened with RHD. 
Weak infrastructure and limited resources are key barriers to programme implementation 
and thus RHD control in LMICs.[2] Integrated care is known for its health system 
strengthening features and holistic approach to health care.[10,11] Therefore, an integrated 
approach could prove to be useful for the design and implementation of future RHD 
prevention and care. By making use of monitoring and evaluation tools, this review will 
identify the best practices in RHD care and provide technical assistance for countries 
seeking to effectively and efficiently integrate RHD-related health services into existing 
health systems. 
The scope of this literature review is broad and first describes the pathogenesis, diagnosis 
and treatment of GAS, ARF, and RHD. Thereafter, the development of prevention and 
control programmes is discussed within the framework of integrated care, providing 
context for the concluding discussion. 
 
2. PATHOGENESIS, DIAGNOSIS, AND TREATMENT 
 
2.1 Group A Streptococcus 
 
2.1.1 Properties and Pathogenesis 
 
Streptococcus pyogenes, or group A Streptococcus (GAS), is a beta-hemolytic species of 
Gram-positive bacteria which mostly affects human pharyngeal or dermal epithelial 
cells.[12] The GAS bacterium itself is made up of a cell wall, surrounded by Group A 
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carbohydrate, protected by a hyaluronic acid capsule (Figure 1).[13] M, T, and R surface 
proteins are extracellular molecules which interact with the hosts’ cells.[13] M proteins have 
been extensively studied since their discovery by Rebecca Lancefield during the early 
1900s.[14] More than 200 distinct M protein serotypes have been identified based on the 
heterogeneous amino N-terminus of the protein.[15,16] This has allowed for the subtyping 






Molecules produced by GAS bacteria, known as virulence factors, act to circumvent the 
host’s natural defences and exploit the inflammatory response, allowing for infection and 
survival of GAS within the body.[12] Initially, the hyaluronic acid capsule of GAS together 
with surface M proteins and C5a peptidase enzymes prevent phagocytosis of the 
bacteria.[17–21] Adhesion molecules anchored to the surface of the bacterial cell allow for 
Figure 2: A simplified diagram of a group A streptococcus bacterium. Adapted from [86] 
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the attachment of GAS to the mucosal layer of the pharynx in a lock-and-key manner.[22] 
Streptokinase (SK), a potent plasminogen activator secreted by the bacteria, then enables 
the movement of GAS across normal tissue barriers.[23] 
An inflammatory response may follow bacterial infection and colonization, resulting in 
clinical symptoms of pharyngitis.[13] Alternatively, GAS might remain dormant in the body 
and the individual will be asymptomatic. Both infected and carrier individuals can transmit 
GAS to a healthy person via direct contact, such as respiratory droplets, or through 
contamination of inanimate objects.[24,25] Children have the highest incidence of both 
respiratory and skin GAS infection.[24,26] 
2.1.2 Clinical Features and Diagnosis 
 
Patients with symptomatic GAS pharyngitis infection may present with sudden onset of a 
sore throat, fever, headache, nausea, patchy tonsillopharyngeal exudates, a scarlatiniform 
rash, and tonsillopharyngeal inflammation.[27] These symptoms are non-specific and 
overlap with the clinical features of non-streptococcal pharyngitis.[27]. Therefore, 
microbiological laboratory testing is required to make a definitive GAS pharyngitis diagnosis. 
Culturing throat swab specimens on a sheep blood agar plate (BAP) remains the gold 
standard for determining whether GAS is present in the pharynx.[28,29] The culturing 
process requires samples to be stored and transported as soon as possible under specific 
conditions to the laboratory for incubation of at least 12 hours.[30] In resource-constrained 
settings, infrequent transport and imperfect storage conditions act as barriers to patient 
diagnosis and treatment.[31] Most clinicians in LMICs have to diagnose GAS pharyngitis 
based on patient signs and symptoms alone, for example in Dar es Salaam, Tanzania, where 
laboratory facilities are absent.[32] 
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Rapid antigen detection tests (RADTs) offer a faster, point of care diagnosis option. While 
RADTs seem to solve the obvious diagnostic barriers faced by many LMICs, this tool is 
expensive and has yet to be validated for these settings.[33] In high-income settings where 
RADTs are used, throat cultures are still necessary to confirm a negative test due to the 
varying specificity of the RADT.[27,34] 
2.1.3 Treatment 
 
Once diagnosed, treatment with antimicrobial medication is required for 10 days in order 
to eradicate GAS from the pharynx.[27] A course of oral antibiotics may be prescribed, but 
intra-muscular administration of benzathine penicillin G (BPG) is preferable.[27] Timely 
diagnosis and administration of suitable primary prophylaxis (Table 1) can prevent acute 
rheumatic fever (ARF), resolve clinical signs and symptoms, decrease contagiousness and 
therefore transmission, allowing the patient to return to their regular activities.[27] 
Table 1: Infectious Diseases Society of America antibiotic regimens for group A streptococcal pharyngitis.[35] 
 








Penicillin V Oral Children: 250 mg twice daily or 3 times daily; 
adolescents and adults: 250 mg 4 times daily 





Intramuscular <27 kg: 600 000 U; ≥27 kg: 1 200 000 U 1 dose 
 
 Cephalexin Oral 20 mg/kg/dose twice daily (max = 500 
mg/dose) 
10 days 




Clindamycin Oral 7 mg/kg/dose 3 times daily (max = 300 
mg/dose) 12 mg/kg once daily (max = 500 
mg) 
10 days 
 Azithromycin Oral 7.5 mg/kg/dose twice daily (max = 250 
mg/dose) 
5 days 
 Clarithromycin Oral 30 mg/kg once daily (max = 1 g) 10 days 
Amoxicillin Oral 50 mg/kg once daily (max = 1000 mg); 
alternate: 
25 mg/kg (max = 500 mg) twice daily 
10 days 
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2.2 Acute Rheumatic Fever 
 
2.2.1 Development of Acute Rheumatic Fever 
 
Acute rheumatic fever (ARF) may occur in 0.3-3% of untreated individuals as a delayed 
sequel to GAS infection following an immune response in the body.[12] GAS-specific 
antigens are identical to those found in cardiac muscle, synovial tissue or neuronal tissue of 
the host.[36] This process, known as molecular mimicry, results in an autoimmune response 
through cross-reacting antibodies.[37,38] Importantly, recurrent ARF episodes are more 
likely to occur with repetitive GAS infections which are left untreated.[39] While the exact 
pathogenic mechanisms of ARF are poorly understood, the incurred tissue damage results in 
the clinical features of ARF. 
2.2.2 Clinical Features and Diagnosis 
 
The inflammatory process which implicates the heart, joints, and brain of the host manifests 
as carditis, arthritis, and Sydenham chorea, respectively.[40] Associated signs and symptoms 
may include fever, joint pain, involuntary muscle movements and a non-itchy rash.[41] In the 
absence of a confirmatory biological test, ARF remains a clinical diagnosis. The Jones Criteria 
was first compiled by Dr T Duckett Jones in 1944 and has since undergone several revisions, 
remaining the global clinical diagnostic gold standard for ARF.[42,43] The latest revision by 
the American Heart Association released in 2015 has considered more modern 
epidemiological data on ARF together with the evolution of essential technologies like 
echocardiography – an ultrasound of the heart.[44] Clinical symptoms are categorised into 
major and minor criteria for ARF diagnosis according to the population at risk (Table 2). In 
order for an individual to receive a confirmatory diagnosis of initial ARF, they need to 
present with 2 major manifestations or 1 major and 2 minor, as well as laboratoryevidence 
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for previous GAS infection.[44] For a diagnosis of recurrent ARF, a patient must have a 
history of GAS infection with 2 major or 1 major and 2 minor or 3 minor criteria.[44] Carditis 
is heavily implicated in the progression to RHD and remains the most common and severe 
manifestation of ARF, affecting close to 80% of patients.[45,46] Thus, it is strongly 
recommended that carditis be assessed by echocardiography in order to establish ARF 
diagnosis.[44] 
Table 2: Summary of the 2015 Jones criteria for diagnosing patients with acute rheumatic fever.[44] 
 
 Low-risk population* Moderate- and high-risk populations 
Major Criteria   
Carditis Clinical and/or subclinical Clinical and/or subclinical 
Arthritis Polyarthritis Monoarthritis, polyarthritis and/or 
polyarthralgia 
  Chorea  
Erythema marginatum 
 
Carditis Prolonged PR interval, accounting for age variability 






ESR ≥60 mm in the first 




ESR ≥30 mm/h and/or CRP ≥3.0 mg/dL 
 
ARF, acute rheumatic fever; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate 
*Low-risk populations are those with ARF incidence ≤2 per 100 000 school-aged children or all-age 





Patients experiencing signs and symptoms of ARF require secondary antibiotic prophylaxis in 
order to return to health and prevent recurrent attacks. This is achieved through regular BPG 
administration, which can be oral or injected, for at least 10 years following the initial 
attack.[47] BPG injected intramuscularly is recognised as being more effective than oral 
doses with a reduction in the reoccurrence of ARF by 87-97%, however there is disputeover 
Minor Criteria 
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how regular the injections should be given.[48,49] Two- or three-weekly injections are 
believed to be more effective in preventing ARF reoccurrence [48], but adherence is 
problematic. Patients from LMICs were found to have better adherence to a 4-weekly 
regimen compared to a 3-weekly or 2-weekly regimen [50]. Often, the lack of key 
infrastructure to deliver BPG influences adherence rates. This is demonstrated in New 
Zealand where patient compliance is reportedly higher among those receiving BPG from 
local ARF/RHD register programmes compared to primary health care facilities.[51] 
Importantly, secondary prophylaxis is recognised as being the most cost-effective 
strategy to control recurrent episodes of ARF and its progression to RHD.[52] 
2.3 Rheumatic Heart Disease 
 
2.3.1 Development, Clinical Features and Diagnosis 
 
RHD, a chronic condition, is characterised by lesions to the heart valves which arise as a 
consequence of prolonged insults to the cardiac tissue during ARF. The mitral and aortic 
valves (Figure 2) are most commonly implicated in RHD, resulting in an abnormal heart 
sounds and haemodynamic effects.[53] In patients with a known history of ARF, it is 
assumed that valvular abnormalities represent RHD.[53] 
Until the advent of echocardiography, clinicians used a stethoscope to non-invasively listen 
to heart sounds to diagnose patients suspected of having RHD.[53] The superior sensitivity 
and specificity of echocardiography has brought to light a truer, more realistic burden of 
subclinical RHD which was previously underestimated in many regions of the world.[54,55] 
Recently, the hand-held echocardiogram has gained a lot of attention for its affordability, 
portable nature, and ease of use. While it lacks the spectral Doppler feature of the standard 
echocardiogram, the hand-held device is viewed as a promising screening tool for subclinical 
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RHD, particularly for remote or resource constrained settings.[49,56] A systematic review is 
currently underway examining the diagnostic accuracy compared to standard 































Tertiary care involves managing the complications associated with RHD. Often, it is 
necessary for patients to undergo costly surgery to repair or replace damaged valves of the 
heart, followed by post-operative care. This is especially the case in developing regions 
where RHD patients tend to present for care at advanced stages of the disease.[58] 
Unfortunately, cardiac facilities in LMICs are severely lacking with only 22 cardiac centresfor 
Figure 3: Line drawing showing the chambers and valves of the heart. RA, right atrium; RV, right 
ventricle; LV, left ventricle; LA, left atrium. Anatomical line drawing downloaded from: 
http://getdrawings.com/anatomical-heart-drawing. 
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the estimated 1 billion people residing in sub-Saharan Africa.[59,60] Patients are required to 
travel cross-country to receive life-saving surgical interventions or rely on humanitarian 
cardiac teams which visit once or twice a year.[59] Team Heart, a non-governmental 
organization based in the United States, has been travelling to Rwanda on an annual basis 
since 2008 to provide care for critical RHD patients.[61] Over the past 10 years, 200 valve 
implants have been completed by the team.[62] 
Following valve replacement, anticoagulants may be prescribed which, if not managed 
correctly, puts the patient at great risk of thromboembolism or haemorrhage.[63,64] In 
order to avoid such outcomes, the patient’s International Normalised Ratio (INR) needs to 
be regularly monitored.[65] Quality follow-up and INR facilities are therefore essential for 
post- operative care of patients. Unfortunately, access to point of care testing is lacking in 
low resource settings experiencing endemic patterns of RHD.[64] The REMEDY study, a 
register of RHD patients in 12 African countries, found only 28.3% of RHD patients to be in 
the therapeutic INR range.[66] 
 
3. ADDRESSING THE BURDEN OF RHEUMATIC HEART DISEASE 
 
RHD is a preventable condition which disproportionately affects poverty stricken children 
and young adults living in rural or resource-limited areas.[1] Aside from the desperate need 
to upscale cardiac surgical services in LMICs, as recently outlined in the Cape Town 
Declaration,[60] a significant barrier to the control of RHD lies within the implementation of 
effective primary and secondary prevention in these communities.[67] Therefore, from a 
health systems perspective, investigation into an effective method of RHD programme 
implementation is appropriate. 
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3.1 Programme Design and Implementation 
 
The health care system is viewed as dynamic and complex, with many interdependent 
interacting components.[68] The implementation of an intervention into a health system is 
believed to be influenced by a number of key factors such as the nature of the problem, the 
type of intervention, adoption system, characteristics of the health system, and the overall 
context in which this all occurs (Figure 3).[69] With this considered, health services are 
typically delivered in a vertical, horizontal, or diagonal manner, each with their own defining 
characteristics. 
 
Figure 4: Factors influencing the implementation of a new health intervention. Adapted from [69]. 
 
Vertical (non-integrated) programmes are typically disease- or service-specific.[10] They 
deliver stand-alone services in which dedicated health workers provide care to a targeted 
population.[10] These types of programmes have been famously effective for the 
eradication of vaccine-preventable diseases such as smallpox.[70] More recent use of 
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vertical programmes have been in targeting infectious diseases in middle-income regions 
such as Latin America and North Africa, however the trade-offs of this type of service 
delivery involves diverting clinical and human resources away from other diseases and 
possible interference by international donors.[10,64] For example, in Ethiopia, disease- 
specific funding thwarted efforts to strengthen the health system.[71,72] 
By the horizontal design, more commonly known as integrated, services are usually 
delivered through the national health care system and are commonly believed to be more 
sustainable, providing a holistic approach to health.[10] Neglected tropical diseases have 
previously benefited from integrated control programmes, such as schistosomiasis control 
in Cameroon which simultaneously worked to strengthen the primary health care 
system.[11] This is in line with the World Health Organization’s health system-based 
definition, which highlights integrated care as “an approach to strengthen people-centred 
health systems through the promotion of the comprehensive delivery of quality 
services”.[73] However, one must consider that the speed and extent of integrating an 
intervention is highly influenced by the aforementioned key factors.[69] For example, the 
ability for a programme to be fully integrated may be limited by context-specific constraints 
like as financial restrictions on the health system or complex relationships among levels of 
the government.[69] 
There has been a longstanding debate about which of the above two approaches is superior 
for disease interventions; Atun and colleagues point out that the reality of health care 
delivery is too complex to confine an intervention to the binary distinction of integrated or 
not integrated.[69] Realistically, programmes vary in their extent of integration or 
verticality according to the nuances of the problem being addressed, the proposed solution, 
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and the context in which this all occurs.[74] The diagonal approach incorporates elements of 
both vertical and integrated programmes, designed to strengthen primary health care while 
performing disease specific activities; it has been suggested that a diagonal approach might 
be well-suited to tackling RHD.[39] 
3.2 Integrating RHD control programmes 
 
According to the WHO, a national RHD programme should include primary and secondary 
activities, health education, training of healthcare providers, epidemiological surveillance, 
and community involvement.[2] Using elements of integration adds to the sustainability of 
such a programme as existing health infrastructure is used to cover the primary, secondary, 
and tertiary levels of care. This is naturally useful for RHD which has its origins in an 
infectious disease and an autoimmune response, thus intersecting a number of specialities 
and levels of care.[75] 
The WHO first began efforts to address the burden of RF and RHD in 1950s,[3,76] and in 
1985 launched the first global programme for the prevention and control of ARF and RHD in 
16 developing countries.[77] This was also the first attempt at integrating ARF and RHD care 
into existing health structures. Secondary prevention efforts included setting up a central 
register for ARF and RHD patients as well as extensive dissemination of health education to 
healthcare professionals and the general public.[77] The goal was to reduce the burden of 
ARF and RHD by creating a comprehensive programme for the local governments to sustain. 
While the paper indicates that there was a lowered reoccurrence rate of ARF, most 
countries struggled with basic components required for RHD control, such as the constant 
provision of penicillin and nearby laboratory facilities.[77,78] The underlying issue was 
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affordability, and only a few countries expanded the local RHD control efforts beyond the 
pilot programme. 
Cuba was one of the countries which ensued with the WHO’s comprehensive RHD control 
initiative, and is a widely cited example for its successful reduction of the burden of ARF and 
RHD in the province of Pinar del Rio.[79] The researchers attribute this success to the means 
of programme implementation, which did not implicate resources outside of the existing 
healthcare system’s capacity.[79] Instead, the primary and secondary prevention 
programme was funded by Cuba’s ministry of health and delivered through local hospitals 
and primary healthcare facilities.[79] Similarly, a secondary prevention programme was set 
up in Northern India which made use of existing educational channels to train teachers and 
healthcare workers, and used local clinics for a registry.[80] The community referral network 
for suspected ARF and RHD cases resulted in 77 patients being registered over the two year 
period.[80] The 85-95% secondary prophylaxis compliance was attributed to continued 
educational efforts, a prophylaxis card dating upcoming injections, and close follow-up of 
defaulting patients.[80] The number of cases detected in the intervention block increased  
by four times over the course of the study, whereas there were only 3 additional cases 
identified in the control block.[80] The intervention and control blocks populations appear to 
have been exchangeable, which adds to the reliability of the study findings, however no 
statistical analysis was performed. 
A notably successful primary prevention programme was conducted during the 1980s in 
Costa Rica. The programme focused on improving the diagnosis and treatment of GAS 
pharyngitis by educating healthcare workers and improving the access to care by increasing 
the number of peripheral clinics and extending working hours.[81] The standard treatment 
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regimen was also changed from oral penicillin to intramuscular administration of BPG. These 
relatively small-scale changes were able to produce a steady decline in the national 
incidence of rheumatic fever over a five year period.[81] Other primary prevention RHD 
programmes have been successfully implemented through school systems. In a controlled 
trial conducted in Southern China, students with a GAS positive throat culture either 
received school-administered primary prophylaxis straightaway, or were notified to seek 
care from their regular medical provider.[82] Students receiving prompt sore throat 
treatment had a significantly lower GAS prevalence compared to that of the control group 
after a 3 month period.[82] 
There is emerging evidence for integrated tertiary care RHD programmes, which are being 
investigated as a cost-saving and safe means of follow-up care for patients. In 2009, a nurse 
practitioner (NP) led clinic was established in an ambulatory setting in New Zealand.[83] The 
aim was to manage and care for patients following valvular heart disease surgery, including 
the promotion of a healthier lifestyle choices with tailored smoking cessation interventions 
and referral to diabetes clinics where necessary.[83] RHD patients exhibited a high 
thromboembolic risk profile, but the NP clinic provided a supportive environment by 
reinforcing the importance of anticoagulation adherence and maintaining INR targets.[83] 
More recently in Rwanda, an advanced non-communicable disease (NCD) care programme 
was embedded into three rural district hospitals as a step toward decentralised follow-up 
care for RHD patients post-surgery.[84] Patients on anticoagulants were to be seen at least 
once a month, with transport assistance provided for the lowest income groups.[84] INR was 
checked during 96% of the visits, and 93% of post-operative patents were receiving penicillin 
to prevent ARF.[84] By using this model, an impoverished population affected by RHD was 
provided with close post-operative care. While the NP clinic anddecentralised 
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programmes have yet to be compared to the standard of care, they present alternative 
models of care for RHD and other valve surgery patients post-operation where care is so 
obviously lacking. 
 
4. SCOPE OF THIS SYSTEMATIC REVIEW 
 
4.1 A framework for analysis 
 
Integration is a complex concept which is not bound to a single definition. Further, the 
means of assessing the nature and extent of an integrated programme has been 
inconsistent. A systematic approach to analysing the integration of RHD programmes is 
required in order to advise on the success or failure of such an approach for future care. 
Atun and colleagues describe a conceptual framework for assessing integration of a targeted 
health intervention into the health system; they define integration as “the extent, pattern, 
and rate of adoption and eventual assimilation of health interventions into critical health 
system functions”.[69] These critical health system functions are: (i) stewardship and 
governance, (ii) financing, (iii) planning, (iv) service delivery, (v) monitoring and evaluation, 
and (vi) demand generation.[69] A brief explanation of these functions as well as the criteria 
for determining the extent of their integration are outlined in Table 3. By bringing together 
certain elements of the health system which affect the adoption, diffusion and assimilation 
of a health intervention, a macro- and micro-analysis of integration into the health system is 
made possible.[69] The conceptual framework therefore provides a novel method for the 
systematic analysis of healthcare programmes which will be used in this study to assess 
RHD-related care interventions and advise future programme implementation. 
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Table 3: Criteria for determining the extent of integration for each health system function.[69,74] 
 
 Fully integrated Partially integrated Not integrated 
Stewardship and 
Governance 
Oversight and guidance. 
When the governance 
arrangements for the 
intervention are the same 
as those for the general 
health services or the local 
or national administrative 
structures. 
The responsibility is 
shared by the existing 
general health care 
system and a specific 
structure created 
purposely for the 
intervention. 
When accountability remains 
exclusively with dedicated 
specialist entities charged with 
implementation and 
management of health 
interventions, without 
involvement of the general 
health care system. 
Financing 
The pooling of financial 
resources and the 
provider-payment 
methods used to allocate 
these. 
Funding is provided 
entirely through the 
national or regional general 
health care budget. 
For example, where 
earmarked funding was 
provided by the United 
States Agency for 
International 
Development (USAID) 
but channeled through 
the PHC system. 
When financing is provided 
directly to an intervention and 
addressing only a particular 
disease or problem; or directly 
funded by an external donor. 
Planning 
Activities, processes and 
systems for needs 
assessment, priority 
setting, and resource 
allocation. 
If the decision-making in 
relation to the above three 
areas is undertaken by 
institutions/stakeholders 
who are involved in the 




planning is retained by 
those managing the 
health intervention but 
involves a range of 







When the decision-making 
focused solely on the 
intervention without 
consideration of general health 
care activities. This may include 
specific national government 




dimensions of the 
programme. 
If their provision is the 
responsibility of general or 
multi-purpose health 
worker. 
Where there is shared 
responsibility for the 
provision of services 
between general health 
workers and the health 
intervention staff; 
purpose trained 
volunteers; when service 
delivery for a number of 
interventions is linked. 
A number of interventions rely 
solely on single purpose workers 
and have no integration with 




Use of shared indicators 
and establishment of 
integrated data collection, 
recording, analysis and 
reporting systems. 
When M&E were 
undertaken jointly by 
staff from the regional 
health services and the 
control programme. 
When M&E is undertaken 
independently by the sponsor, 
institution, or volunteers of the 
implementing organisation. 
Demand generation 
The use of appropriate 
financial incentives and 
monetary support, 
insurance, or information, 
education and 
communication activities 
designed to change 
behaviour. 
If mechanisms used to 
create financial incentives 
or education and 
communication activities 
are provided jointly with 
the general services or are 
delivered by primary health 
care workers. 
When education is 
provided jointly by the 
targeted programme 
staff and regional health 
workers. 
Where information campaigns 
related to health interventions 
are stand-alone activities, 
focusing solely on a single 
problem or disease, and 
delivered by single-purpose 
health workers or volunteers. 
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Integration can occur along more than one dimension (each health system function) and to 
various extents (fully, partially, or not integrated). In order to assess the effectiveness of a 
programme, another analytical framework is required: the results chain (Figure 4). 
Comprising inputs, activities, outputs, outcomes, and impact, the results chain is a causal 
logic model which is used commonly in monitoring and evaluation to assess the relative 
impact of an intervention.[85] These types of evaluations are used to inform decision 
makers, government officials, and other stakeholders about the effectiveness of an 
intervention. Thus, the results chain is a useful complement for the Atun framework when 







4.2 Discussion and potential impact of this work 
 
Atun and colleagues conducted a review to assess the integration of interventions for 
neglected tropical diseases, nutrition, immunization, child health and development, family 
planning, and HIV/AIDS.[74] Contrary to the popular notion that health programmes are 
either vertical or horizontal (integrated), it was found that most programmes were partially 
integrated, and that the extent of integration varied across each of the six critical health 
system functions.[74] It was strongly argued that such heterogeneity was desirable given 
differences in health system design, capacity, and priorities.[74] For some programmes, 















Figure 4: The results chain framework. 
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and sustainable. For other programmes, such as those that provide clinical care for diabetes 
and other complex chronic diseases, episodic community-based activities are unlikely to 
achieve significant health impact or be financially sustainable, and integrated approaches 
delivered at primary health centres are needed.[74] 
Amongst non-communicable diseases, RHD and its antecedents represent a unique set of 
considerations that span a wide spectrum of health system activities. Some aspects of RHD 
prevention have much in common with infectious disease control. For example, surveillance 
and notification policies are needed in order to identify and respond quickly to ARF 
outbreaks and ramp up primary prevention activities. Other aspects – such as secondary 
prevention – have more in common with clinic-based care for hypertension, diabetes, and 
HIV/AIDS. The frequent need for (highly-effective) tertiary surgical and medical care also 
creates additional complexity. In light of all this, there is unlikely to be a “one size fits all” 
approach to RHD prevention and control in LMICs. What is needed, which this systematic 
review will begin to provide, is evidence regarding efficient models of care and best 
practice. A robust analysis of the purpose, extent, and nature of integration for programmes 
and services will be of interest to decision makers in resource-constrained settings as well 
as those in more developed regions wishing to scale up RHD-related activities. We anticipate 
that this review will raise more questions than propose solutions and view this as a first step 





1 Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden 
of Rheumatic Heart Disease, 1990–2015. N Engl J Med 2017;377:713–22. 
doi:10.1056/NEJMoa1603693 
2 WHO. Rheumatic fever and rheumatic heart disease. 2004. doi:10.1016/S0140- 
6736(11)61171-9 
3 WHO. World Health Organization technical report series: Prevention of rheumatic 
fever. Geneva, Switzerland: 1957. 
4 Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in 
the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 
1985;72:1155–62.http://www.ncbi.nlm.nih.gov/pubmed/4064266 (accessed 11 Dec 
2017). 
5 Remenyi B, Carapetis J, Wyber R, et al. Position statement of the World Heart 
Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol 
2013;10:284–92. doi:10.1038/nrcardio.2013.34 
6 WHO. Global action plan for the prevention and control of noncommunicable 
diseases 2013-2020. World Heal Organ 2013;:102. doi:978 92 41506236 
7 WHO. NCDs | 71st World Health Assembly adopts resolution calling for greater action 
on rheumatic heart disease. World Health Organization 2018. 
http://www.who.int/ncds/management/rheumatic-heart-disease-resolution/en/ 
(accessed 13 Aug 2018). 
8 Yacoub M, Mayosi B, ElGuindy A, et al. Eliminating acute rheumatic fever and 
rheumatic heart disease. Lancet 2017;390:212–3. doi:10.1016/S0140-6736(17)31608- 
2 
9 Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart 
disease in Africa: the Addis Ababa communique. Cardiovasc J Afr 2016;27:184–7. 
doi:10.5830/CVJA-2015-090 
10 Atun R, Bennett S, Duran A. When do vertical (stand-alone) programmes have a place 
in health systems? 2008. 
http://www.who.int/management/district/services/WhenDoVerticalProgrammesPlac 
eHealthSystems.pdf 
11 Cline BL, Hewlett BS. Community-based approach to schistosomiasis control. Acta 
Trop. 1996;61:107–19. doi:10.1016/0001-706X(95)00118-X 
12 Cunningham MW. Pathogenesis of Group A Streptococcal Infections. 2000;13:470– 
511.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC88944/pdf/cm000470.pdf 
(accessed 22 Jan 2018). 
13 Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus pyogenes: Basic Biology to Clinical 
Manifestations. Princ Pract Infect Dis 2005;:1050. doi:10.1016/B978-0-12-397169- 
2.00038-X 
21  
14 Lancefield RC. The antigenic complex of streptococcus haemolyticus: I. 
Demonstration of a type-specific substance in extracts of streptococcus haemolyticus. 
J Exp Med 1927;47:91–103. doi:10.1084/jem.47.1.91 
15 Mcmillan DJ, Drèze P-A, Vu T, et al. Updated model of group A Streptococcus M 
proteins based on a comprehensive worldwide study. Clin Microbiol Infect 
2013;19:E222–9. doi:10.1111/1469-0691.12134 
16 Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A 
streptococci: systematic review and implications for vaccine development. Lancet 
Infect. Dis. 2009;9:611–6. doi:10.1016/S1473-3099(09)70178-1 
17 Uchida N, Lee JS, Horst RJ, et al. Regulation of inflorescence architecture by 
intertissue layer ligand-receptor communication between endodermis and phloem. 
Proc Natl Acad Sci 2012;109:6337–42.doi:10.1073/pnas.1117537109 
18 Zocchi G. Mechanical measurement of the unfolding of a protein. Europhys Lett 
1996;35:633–8. doi:10.1209/epl/i1996-00163-6 
19 Cleland EE. National Academy of Sciences | Proceedings of the National Academy of 
Sciences of the United States of America. 2015;98:5446–51. 
doi:10.1073/pnas.1207851 
20 Scott JR, Guenthner PC, Malone LM, et al. Conversion of an M- group A streptococcus 
to M+ by transfer of a plasmid containing an M6 gene. J Exp Med 1986;164:1641–51. 
doi:10.1084/JEM.164.5.1641 
21 Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. 
J Immunol 1962;89:307–13.http://www.ncbi.nlm.nih.gov/pubmed/14461914 
(accessed 18 Feb 2018). 
22 Beachey EH, Courtney HS. Bacterial adherence: the attachment of group A 
streptococci to mucosal surfaces. Rev Infect Dis 1987;9 Suppl 5:S475- 
81.http://www.ncbi.nlm.nih.gov/pubmed/3317744 (accessed 23 Jan 2018). 
23 Boyle MDP, Lottenberg R. Plasminogen activation by invasive human pathogens. 
Thromb. Haemost. 1997;77:1–10.http://www.ncbi.nlm.nih.gov/pubmed/9031440 
(accessed 23 Jan 2018). 
24 Patterson MJ. Streptococcus. In: Baron S, ed. Medical Microbiology. 1996. 
http://www.ncbi.nlm.nih.gov/pubmed/21413248 (accessed 22 Jan 2018). 
25 Wong SS, Yuen K-Y. Streptococcus pyogenes and re-emergence of scarlet fever as a 
public health problem. Emerg Microbes Infect 2012;1:e2. doi:10.1038/emi.2012.9 
26 Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J 
Paediatr Child Health 2007;43:203–13.doi:10.1111/j.1440-1754.2007.01051.x 
27 Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis 
and Management of Group A Streptococcal Pharyngitis: 2012 Update by the 
Infectious Diseases Society of America. Clin Infect Dis 2012;55:e86–102. 
doi:10.1093/cid/cis629 
22  
28 Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A 
streptococci. Clin Microbiol Rev 2004;17:571–80, table of contents. 
doi:10.1128/CMR.17.3.571-580.2004 
29 Bisno AL, Gerber MA, Gwaltney Jr. JM, et al. Practice guidelines for the diagnosis and 
management of group A streptococcal pharyngitis. Infectious Diseases Society of 
America. Clin Infect Dis 2002;35:113–25. doi:10.1086/340949 
30 Johnson DR, Kaplan EL, Sramek J, et al. Laboratory diagnosis of group A streptococcal 
infections. 1996. 
31 Colquhoun SM, Carapetis JR, Kado JH, et al. Rheumatic heart disease and its control in 
the Pacific. Expert Rev Cardiovasc Ther 2009;7:1517–24. doi:10.1586/erc.09.145 
32 Bergmark R, Bergmark B, Blander J, et al. Burden of disease and barriers to the 
diagnosis and treatment of group A streptococcal pharygitis for the prevention of 
rheumatic heart disease in Dar Es Salaam, Tanzania. Pediatr Infect Dis J 
2010;29:1133–5. doi:10.1097/INF.0b013e3181ed18ab 
33 Brink AJ, Van Wyk J, Moodley VM, et al. The role of appropriate diagnostic testing in 
acute respiratory tract infections: An antibiotic stewardship strategy to minimise 
diagnostic uncertainty in primary care. South African Med J 2016;106:554. 
doi:10.7196/SAMJ.2016.v106i6.10857 
34 Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A 
streptococci. Clin Microbiol Rev 2004;17:571–80. doi:10.1128/CMR.17.3.571- 
580.2004 
35 Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and 
management of group a streptococcal pharyngitis: 2012 update by the infectious 
diseases society of America. Clin Infect Dis 2012;55:e86–102. doi:10.1093/cid/cis629 
36 Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic 
heart disease. Nat Rev 2016;2. doi:10.1038/nrdp.2015.84 
37 Gorton D, Govan B, Olive C, et al. B- and T-cell responses in group A streptococcus M- 
protein- or peptide-induced experimental carditis. Infect Immun 2009;77:2177–83. 
doi:10.1128/IAI.01514-08 
38 Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: The 
streptococcal connection. Int. Rev. Immunol. 2014;33:314–29. 
doi:10.3109/08830185.2014.917411 
39 Wyber R, Gasser AG, Thompson D, et al. Tools for Implementing RHD Control 
Programmes (TIPS) Handbook. Perth, Australia: : World Heart Federation and RhEACH 
2014. 
40 Sika-Paotonu D, Beaton A, Raghu A, et al. Acute Rheumatic Fever and Rheumatic 
Heart Disease. 2017 Mar 10 [Updated 2017 Apr 3]. In: Ferretti J, Stevens D, Fischetti 
V, eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma 
City (OK): : University of Oklahoma Health Sciences Center 2016. 1–57. 
doi:10.1038/nrdp.2015.85 
23  
41 Marijon E, Mirabel M, Celermajer DS, et al. Rheumatic heart disease. Lancet 
2012;379:953–64. doi:10.1016/S0140-6736(11)61171-9 
42 Jones TD. The diagnosis of rheumatic fever. J Am Med Assoc 1944;126:481–4. 
doi:10.1001/jama.1944.02850430015005 
43 Beaton A, Carapetis J. The 2015 revision of the Jones criteria for the diagnosis of 
acute rheumatic fever: Implications for practice in low-income and middle-income 
countries. Heart Asia. 2015;7:7–11. doi:10.1136/heartasia-2015-010648 
44 Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones criteria for the diagnosis 
of acute rheumatic fever in the era of Doppler echocardiography a scientific 
statement from the American heart association. Circulation 2015;131:1806–18. 
doi:10.1161/CIR.0000000000000205 
45 Bhardwaj R, Sood A. Clinical Profile of Acute Rheumatic Fever Patients in a Tertiary 
Care Institute in Present Era. J Assoc Physicians India 2015;63:22– 
4.http://www.ncbi.nlm.nih.gov/pubmed/26591165 (accessed 5 Mar 2018). 
46 Caldas ÁM, Terreri MTRA, Moises VA, et al. What is the true frequency of carditis in 
acute rheumatic fever? A prospective clinical and doppler blind study of 56 children 
with up to 60 months of follow-up evaluation. Pediatr Cardiol 2008;29:1048–53. 
doi:10.1007/s00246-008-9242-z 
47 Carapetis J, Brown A, Maguire G, et al. The Australian guideline for prevention, 
diagnosis and management of acute rheumatic fever and rheumatic heart disease. 
2012. doi:10.1016/j.hlc.2007.12.002 
48 Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. 
Cochrane Database Syst Rev Published Online First: 2002. 
doi:10.1002/14651858.CD002227 
49 Cramp G, Stonehouse M, Webb R, et al. Undetected rheumatic heart disease revealed 
using portable echocardiography in a population of school students in Tairawhiti,  
New Zealand. N Z Med J 2012;125:53–61.http://www.nzma.org.nz/journal/125- 
1363/xxxx/ (accessed 5 Jul 2018). 
50 Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in 
evidence-based interventions in rheumatic heart disease: The Global Rheumatic 
Heart Disease Registry (the REMEDY study). Eur Heart J 2015;36:1115–22. 
doi:10.1093/eurheartj/ehu449 
51 Culliford-Semmens N, Tilton E, Webb R, et al. Adequate adherence to benzathine 
penicillin secondary prophylaxis following the diagnosis of rheumatic heart disease by 
echocardiographic screening. N Z Med J 2017;130:50–7.www.nzma.org.nz/journal 
(accessed 17 Feb 2018). 
52 Watkins DA, Mvundura M, Nordet P, et al. A cost-effectiveness analysis of a program 
to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba. PLoS 
One 2015;10:e0121363. doi:10.1371/journal.pone.0121363 
53 Reméanyi B, Wilson N, Steer A, et al. World Heart Federation criteria for 
echocardiographic diagnosis of rheumatic heart disease-an evidence-based guideline. 
24  
Nat. Rev. Cardiol. 2012;9:297–309. doi:10.1038/nrcardio.2012.7 
54 Saxena A, Zühlke L, Wilson N. Echocardiographic screening for rheumatic heart 
disease: Issues for the cardiology community. Glob Heart 2013;8:197–202. 
doi:10.1016/j.gheart.2013.08.004 
55 Essop MR, Mayosi BM. Echocardiographic Detection of Latent Rheumatic Heart 
Disease: A Pandora’s Box? Circulation 2017;136:2245–7. 
doi:10.1161/CIRCULATIONAHA.117.030642 
56 Saxena A. Rheumatic heart disease screening by “point-of-care” echocardiography: an 
acceptable alternative in resource limited settings? Transl Pediatr 2015;4:210–3. 
doi:10.3978/j.issn.2224-4336.2015.06.01 
57 Telford LH, Abdullahi LH, Ochodo EA, et al. Standard echocardiography versus 
handheld echocardiography for the detection of subclinical rheumatic heart disease: 
protocol for a systematic review. BMJ Open 2018;8:e020140. doi:10.1136/bmjopen- 
2017-020140 
58 Watson G, Jallow B, Le Doare K, et al. Acute rheumatic fever and rheumatic heart 
disease in resource-limited settings. Arch Dis Child 2015;100:370–5. 
doi:10.1136/archdischild-2014-307938 
59 Yankah C, Fynn-Thompson F, Antunes M, et al. Cardiac surgery capacity in sub- 
Saharan Africa: Quo Vadis? Thorac Cardiovasc Surg 2014;62:393–401. doi:10.1055/s- 
0034-1383723 
60 Zilla P, Bolman RM, Yacoub MH, et al. The Cape Town Declaration on access to 
cardiac surgery in the developing world. J Thorac Cardiovasc Surg 2018;:1–4. 
doi:10.1016/j.jtcvs.2018.06.002 
61 Swain JD, Pugliese DN, Mucumbitsi J, et al. Partnership for sustainability in cardiac 
surgery to address critical rheumatic heart disease in sub-Saharan Africa: The 
experience from Rwanda. World J Surg 2014;38:2205–11. doi:10.1007/s00268-014- 
2559-2 
62 Swain JBD, Sinnott C, Breakey S, et al. Ten-year clinical experience of humanitarian 
cardiothoracic surgery in Rwanda: Building a platform for ultimate sustainability in a 
resource-limited setting. J Thorac Cardiovasc Surg 2018;155:2541–50. 
doi:10.1016/j.jtcvs.2017.11.106 
63 Martin K, Forrest K, Jaiteh L, et al. Post-operative outcomes of gambian children and 
adolescents post valvular surgery for rheumatic heart disease. Arch Dis Child 
2018;103:A110–1. doi:http://dx.doi.org/10.1136/archdischild-2018-rcpch.263 
64 Wyber R, Johnson T, Perkins S, et al. Tools for Implementing Rheumatic Heart Disease 
Control Progammes (TIPs) Handbook. 2nd Ed. Geneva, Switzerland: 2018. 
65 Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the 
Management of Patients With Valvular Heart Disease: Executive Summary. J Am Coll 
Cardiol 2014;129:2440–92. doi:10.1161/CIR.0000000000000029 
66 Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gapsin 
25  
evidence-based interventions in rheumatic heart disease: The Global Rheumatic 
Heart Disease Registry (the REMEDY study). Eur Heart J 2015;36:1115–22. 
doi:10.1093/eurheartj/ehu449 
67 WHO. Rheumatic fever and rheumatic heart disease: Report by the Director-General. 
Geneva, Switzerland: 2018. 
68 Tan J, Wen HJ, Awad N. Health care and services delivery systems as complex 
adaptive systems. Commun ACM 2005;48:36.doi:10.1145/1060710.1060737 
69 Atun R, de Jongh T, Secci F, et al. Integration of targeted health interventions into 
health systems: a conceptual framework for analysis. Health Policy Plan 2010;25:104– 
11.http://dx.doi.org/10.1093/heapol/czp055 
70 Gounder C. The progress of the Polio Eradication Initiative: what prospects for 
eradicating measles? Health Policy Plan 1998;13:212–33. 
71 Assefa Y, Tesfaye D, Damme W Van, et al. Effectiveness and sustainability of a 
diagonal investment approach to strengthen the primary health-care system in 
Ethiopia. Lancet 2018;392:1473–81. doi:10.1016/S0140-6736(18)32215-3 
72 Bennett S, Fairbank A. The System-Wide Effects of the Global Fund to Fight AIDS, 
Tuberculosis and Malaria: A Conceptual Framework. 2003. 
http://www.phrplus.org/Pubs/Tech031_fin.pdf (accessed 22 Oct 2018). 





74 Atun R, de Jongh T, Secci F, et al. A systematic review of the evidence on integration 
of targeted health interventions into health systems. Health Policy Plan 2010;25:1– 
14.http://dx.doi.org/10.1093/heapol/czp053 
75 Dougherty S, Beaton A, Nascimento B, et al. Prevention and control of rheumatic 
heart disease: Overcoming core challenges in resource-poor environments. Ann 
Pediatr Cardiol 2018;11:68. doi:10.4103/apc.APC_135_17 
76 WHO. World Health Organization technical report series: Expert committee on 
rheumatic diseases. Geneva, Switzerland: 1954. 
77 Nordet P, WHO. WHO programme for the prevention of rheumatic fever/rheumatic 
heart disease in 16 developing countries: report from Phase I (1986-90). Bull World 
Health Organ 
1992;70:213.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2393294/pdf/bullwho0 
0041-0063.pdf (accessed 17 Feb 2018). 
78 WHO. WHO global programme for the prevention of rheumatic fever/rheumatic 
heart disease in sixteen developing countries (AGFUND supported) Meeting of 
national programme managers, Geneva: 4-6 November 1986, report (No. 
WHO/CVD/87.1. Unpublished). Geneva, Switzerland: 1987. 
26  
79 Nordet P, Lopez R, Duenas A, et al. Prevention and control of rheumatic fever and 
rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc J Afr 
2008;19:135–40. 
80 Iyengar SD, Grover A, Kumar R, et al. A rheumatic fever and rheumatic heart disease 
control programme in a rural community of north India. Natl Med J India 1991;4:268– 
71. 
81 Arguedas A, Mohs E. Prevention of rheumatic fever in Costa Rica. J Pediatr 
1992;121:569–72. doi:10.1016/S0022-3476(05)81146-1 
82 Lin S, Kaplan EL, Rao X, et al. A School-Based Program for Control of Group A 
Streptococcal Upper Respiratory Tract Infections. Pediatr Infect Dis J 2008;27:753–5. 
doi:10.1097/INF.0b013e31816be02f 
83 McLachlan A, Sutton T, Ding P, et al. A Nurse Practitioner Clinic: A Novel Approach to 
Supporting Patients Following Heart Valve Surgery. Hear Lung Circ 2015;24:1126–33. 
doi:10.1016/j.hlc.2015.04.064 
84 Rusingiza EK, El-Khatib Z, Hedt-Gauthier B, et al. Outcomes for patients with 
rheumatic heart disease after cardiac surgery followed at rural district hospitals in 
Rwanda. Heart. 2018;:heartjnl-2017-312644.doi:10.1136/heartjnl-2017-312644 
85 Gertler PJ, Martinez S, Premand P, et al. Impact Evaluation in Practice. Washington 
DC: : The World Bank 2011. doi:10.1596/978-0-8213-8541-8 
86 Ishaq M, Ishaq S, Khan I, et al. The Hallmarks of Rheumatic Fever in Developing 
Countries (Pakistan and Afghanistan). Ann Paediatr Rheumatol 2016;:11–9. 
doi:10.5455/apr. 012720161201 
1  







Background: Rheumatic heart disease (RHD), a sequel of group A streptococcal pharyngitis, 
is a significant cause of premature deaths, primarily in poverty-stricken communities and 
countries. Following on a 2018 World Health Assembly resolution on RHD, there is 
increasing need for evidence to guide the implementation of successful RHD programmes 
that are integrated into national health systems. 
Objectives: To assess the effectiveness of programmes targeting RHD prevention and 
control according to the extent and nature of integration into the health system. 
Methods: A comprehensive literature search was performed among electronic databases 
and grey literature, complemented by hand searching reference lists, to identify analytical 
and descriptive studies reporting on prevention and control programmes for populations at 
risk for GAS pharyngitis, acute rheumatic fever, and/or RHD. Studies needed to be published 
in English between 1 January 1990 and 31 December 2017. RHD programme integration was 
analysed according to a previously described framework, and programme effectiveness data 
were extracted and analysed using a results chain framework. A meta-analysis was 
performed on secondary prophylaxis adherence. Bias was assessed using the Critical 
Appraisal Skills Programme checklist. This review followed the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidelines. 
PROSPERO registration number: CRD42017076307 
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Results: Six-hundred and fifty-eight publications were identified. Data were extracted from 
five observational studies meeting with the inclusion criteria. Studies were similar in extent 
and nature (health system function) of integration; none of the programmes were 
completely integrated or non-integrated. One study reported on the impact of the 
programme. Secondary prophylaxis adherence improved among partially integrated RHD 
programmes (RR, 1.18 [95% CI, 1.03 to 1.36], 3 studies, n=618). In terms of quality appraisal, 
risk of bias was low in two studies, and indeterminable in the remaining three studies. 
Conclusions: There is evidence that partially integrated RHD programmes are beneficial for 
a number of study outcomes. This review provides a starting point for the design and 
implementation of future RHD programmes by outlining current best practice for 
integration and identifying the key gaps in knowledge. 
Keywords: Group A streptococcus, Rheumatic Fever, Rheumatic Heart Disease, Integrated 
Care, Prevention and Control. 
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Strengths and Limitations 
 
 This is the first systematic review to analyse the integration of prevention and control 
programmes for rheumatic heart disease. 
 The use of multiple complementary conceptual frameworks (health system critical 
functions, type of services delivered, and results chain) provides a unique and 
comprehensive assessment of each programme. 
 We recognise that restricting the search to English may have introduced language and 
publication bias, and that the time period restriction would have excluded older studies 





Rheumatic heart disease (RHD) is a potentially fatal yet preventable condition which begins 
with a sore throat and results in damage to the valves of the heart. RHD is responsible for 
about 300,000 deaths annually, most of which are children and young adults from 
resource-constrained settings.[1] Crowded and unsanitary living conditions enable the 
spread of group A streptococcus (GAS), the infectious agent inducing an autoimmune 
response, resulting in the progression from pharyngitis to acute rheumatic fever (ARF).[2] 
Under- recognition of ARF coupled with inadequate access to medical care often results in 
RHD and sometimes premature death among these patients.[2] 
Strategies to combat disease progression include penicillin primary prophylaxis following 
GAS diagnosis, or secondary prophylaxis for patients diagnosed with ARF.[2,3] In patients 
who present for medical attention late in the disease, heart valve surgery is required to 
repair the damage caused by severe or recurrent episodes of ARF, often followed by a 
lifelong dependence on anticoagulants and penicillin.[4] In countries with endemic patterns 
of RHD, weak infrastructure and limited resources are key barriers to RHD prevention and 
control efforts.[5] 
RHD has been placed on the international agenda, with the World Heart Federation setting 
out to achieve a 25% reduction in premature deaths from ARF and RHD among individuals 
younger than 25 years of age, by the year 2025.[6,7] More recently, the World Health 
Assembly approved the Resolution on Rheumatic Fever and Rheumatic Heart Disease 
thereby committing countries to showing progress in the eradication of RHD.[8] The Addis 
Ababa Communique and Cairo Accord provide key actionable strategies to eradicate RHD 
which includes implementing a multi-sectoral national RHD programme.[9,10] 
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In order to achieve the desired progress, evidence-based prevention and treatment services 
require scaling up in the countries and regions which are still heavily burdened with RHD. A 
possible solution is to design comprehensive prevention and control programmes which are 
integrated into the respective country’s health system, as integrated care has been found to 
have health system strengthening features.[11,12] Thus far, RHD programmes have been 
evaluated using uncontrolled approaches, and there is little evidence on how to efficiently 
integrate RHD-specific activities into broader health systems. 
This systematic review sought to examine previously published reports of RHD prevention 
and control programmes in order to determine the nature and extent of integration, and 
how this integration (or lack thereof) might affect programme success. In doing so, this 
research will synthesise existing evidence and identify additional research that is needed to 




The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines were followed in this systematic review (Appendix 1). This review protocol has 
been published in the PROSPERO International Prospective Register of systematic reviews 
(http://www.crd.york.ac.uk/PROSPERO), registration number CRD42017076307. 
 
2.1 Search Strategy 
 
A comprehensive search strategy (Appendix 2) was used to find studies published in 
PubMed, Cochrane Central Register of Controlled Trials, Scopus, ISI Web of Science, Africa 
Wide and CINAHL. Google Scholar and Global Index Medicus (which includes Latin America 
and the Caribbean database LILACS, as well as World Health Organisation Library 
Information System (WHOLIS)) were searched for grey literature using key search terms. The 
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reference lists of relevant studies were hand searched to further identify possible articles. 
Studies were eligible for screening if they were published in English between 1 January 1990 
and 31 December 2017. 
2.2 Study Selection 
 
After removing duplicate publications, two authors independently screened titles and 
abstracts. Discrepancies were resolved by discussion, after which two reviewers (JA and 
DW) independently scrutinised the full text articles to determine inclusion. Studies were 
included if they reported on a health programme (defined as an intentional effort to expand 
health services) directed at populations at risk for group A streptococcus infection, 
rheumatic fever, and/or rheumatic heart disease. In addition, studies were included if they 
had information on programme characteristics such as the duration and location of the 
programme, the type of services delivered, and the programme inputs, as well as sufficient 
details on at least four of the six key functions of the health system, namely: (i) governance, 
(ii) financing, (iii) planning, (iv) service delivery, (v) monitoring and evaluation, and (vi) 
demand generation. Randomised controlled trials (RCTs), controlled clinical trials (CCTs), 
quasi-experimental, controlled before-and-after studies (CBAs), interrupted time series 
(ITS), or cross-sectional designs were included. “Opinion pieces”, narrative reviews, and 
letters to the editor were excluded. 
2.3 Data Extraction and Analysis 
 
The data extraction form was piloted using five publications (Appendix 3). Data were 
subsequently extracted by JA and checked by DW. A consensus was reached on any 
discrepancies. 
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For each publication, the programme characteristics, extent of integration, and programme 
results were extracted. Programme characteristics included basic data such as target 
population, scale, and duration, as well as detailed data on inputs organised into the six 
“building blocks” used in the WHO health systems framework. The extent of integration was 
characterised for each of the six key functions of the health system and assigned a score 
from 1 to 3 depending on whether the programme was not integrated, partially integrated, 
or fully integrated (or not reported). Integration scores for each of the six key functions 
were summed to a composite score with a maximum value of 18. Appendix 4 provides 
further details on how the extent of integration was scored. A results chain comprising 
programme inputs, activities, outputs, outcomes, and impacts, was populated for each 
study using the extracted data. A meta-analysis of study outcomes was performed using 
Review Manager 5.3.[13] Data were either pooled or presented without totals depending on 
the type of outcome. 
The first six domains of the Critical Appraisal Skills Programme (CASP) checklist were used to 
assess the risk of bias of the included studies.[14] Domains were scored as ‘Y’ (bias absent), 




The search identified 658 publications, of which 94 were duplicates, leaving a total of 564. 
An additional seven articles were found following grey literature and reference list searches. 
During title and abstract screening, 537 studies were excluded. The remaining 34 
publications underwent detailed assessment; a further 29 articles were excluded, mostly 
because of unacceptable study design or insufficient information on programme integration 

















Articles excluded (n=29): 
Incorrect study design: n=15 
Insufficient programme characteristics: n=2 
Intervention criteria not met: n=2 








Global Index Medicus 
n=9 
Web of Science 
n=85 
Duplicates removed, n=94 
Citations identified, n = 564 





Figure 5: Flow diagram of the search process and selection of eligible publications for the systematic review. 
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3.1 Study Characteristics 
 
Table 1 provides summary characteristics of the five studies included in this systematic 
review. All of the studies were observational; three used a cross-sectional design while the 
remaining two used a quasi-experimental (before and after) study design. Four of the five 
studies focused on secondary prevention of RHD,[15–18] though one also had a primary 
prevention component.[16] A single study targeted tertiary care.[19] 
The outcomes measured varied across the studies with none of the studies specifically 
assessing approaches to integrating RHD care as a primary study objective. A variety of 
geographical locations were covered by the included studies, targeting at-risk communities 
in Africa, the Americas, South-East Asia, the Eastern Mediterranean, and the Western Pacific 
region. The shortest study duration was two years while the longest study continued for 10 
years. 
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Table 1: Summary of characteristics of included studies (ordered chronologically) 
Study ID Country and region Programme 
duration 
Description of the 
intervention 
Study outcome(s) measured Level(s) of 
prevention or 
care 
Programme scale: numbers of 
healthcare workers and 
patients involved 
     1° 2° 3°  
Iyengar 
1991[15] 
India: Haryana State, 
Ambala district. 
2 years An ARF/RHD health 
education and training 
programme for health 
workers, teachers, and 
school pupils, as well as the 
registration of new cases and 
prescription of penicillin. 
I. The number and source of: 
suspected case referrals, 
registered cases, and 
confirmed cases of RF and RHD 
(case detection rate) 
II. Adherence to secondary 
prophylaxis. 
   202 healthcare workers and 
773 teachers were trained to 
recognise the signs and 
symptoms of ARF and RHD. Of 
the 254 suspected case 
referrals, 77 were registered 
in health centres, of which 61 






Mali, Zambia, Zimbabwe; 
(Americas) Bolivia, El 
Salvador, Jamaica; 
(Eastern Mediterranean) 
Egypt, Iraq, Pakistan and 
Sudan; (South-East Asia) 
India, Sri Lanka and 
Thailand; (Western 
pacific) China, the 
Philippines and Tonga. 
4 years Personnel training, health 
education and a central 
ARF/RHD register. 
I. Secondary prophylaxis 
coverage. 
II. ARF reoccurrence. 
   Across all of the countries, 24 
398 personnel trained; 33 
651 patients were registered. 
Nordet 
2008[16] 
Cuba: Pinar del Rio. 10 years A community based 
prevention and treatment of 
ARF/RHD through healthcare 
education and training of 
health personnel as well as 
I. The incidence of ARF (new and 
recurrent cases). 
II. The prevalence and severity of 
RHD. 
   All 5 – 25 year old permanent 
residents of the province 
during the study period were 
included (n = 273 933). 
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   the establishment of 





The proportion of patients 
requiring hospitalization. 
 
Ralph Australia: Northern 3 years A continuous quality I. Proportion of patients  6 health centres participated; 
2013[18] Territory.  improvement (CQI) strategy  receiving scheduled BPG. 154 ARF/RHD patients. 
   to improve the II. Proportion of patients  
   documentation and care of  reviewed by their doctor in the  
   ARF/RHD patients.  past two years.  
    III. The quality of data recorded  
     on ARF/RHD patients: ARF  
     episodes and RHD risk category  
     information.  
Kwan Rwanda: Kirehe and 4.4 years Outpatient heart failure I. Distribution of conditions  Each clinic team included 2 
2013[19] Southern Kayonza  services implemented at pre-  (including RHD) among heart nurses and 2 administrative 
 districts.  existing integrated NCD  failure patients. personnel, supervised by 
 clinics at two rural hospitals. II. Programme retention. generalist physicians. Out of 
Portable ECG and algorithms III. Mortality among patients with 237 patients suspected of 
were used for the diagnosis  confirmed diagnoses. heart failure, 192 had a 
and management of patients   confirmed cardiologist 
with suspected heart failure.   diagnosis and were enrolled in 
the heart failure programme. 
ARF, acute rheumatic fever; RHD, rheumatic heart disease 
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3.2 Models of Care: Inputs and Activities 
 
Iyengar and colleagues implemented a secondary prevention programme in Northern India, 
which was financed by a grant from the WHO Arab Gulf programme for development 
(AGFUND).[15] The programme included 202 healthcare workers and 773 teachers (in 147 
schools), who were trained to recognise suspected cases of ARF and RHD. Educational 
materials in the form of posters, pamphlets and heart models further delivered information 
about ARF and how to seek treatment. Through this community-based referral system, 
suspected cases of ARF and RHD could be sent to the nearest health center for diagnosis 
and treatment. Standard diagnostics for ARF and RHD were used. A rural health centre- 
based registry was set up where penicillin injections were administered by pharmacists or 
nurses. Each registered patient received a secondary prophylaxis card and could receive 
treatment at any of the four health centres in the area. 
The World Health Organization initiated a secondary prevention pilot programme in sixteen 
different countries.[17] The Ministry of Health in each country was responsible for the 
operationalisation of the programme, with external funding assistance provided by the 
AGFUND. Each country employed a national programme manager and a multi-disciplinary 
advisory committee. A total of 2 138 doctors, 16 480 school teachers, and 5 780 other 
health personnel received training on ARF and RHD. Group sessions were available for the 
general public. Further education was disseminated by pamphlets, brochures, posters, radio 
and television. A central ARF/RHD register was set up in each country to manage patients 
and deliver secondary prophylaxis through the primary health care system. Guidelines and 
protocols for care delivery were based on the 1988 WHO Technical Report Series. Case 
finding efforts focused on the screening of schoolchildren, hospital retrospective case 
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surveys, and referral of suspected or confirmed ARF/RHD cases from hospitals, private 
clinics or other sources. 
Nordet and colleagues report on a 10-year effort to roll out primary and secondary 
prevention in one province in Cuba (273 933 individuals aged 5-25 in the province were 
included).[16] The programme was organized and administered by an advisory committee 
that was part of the provincial health office. Clinical services and educational materials 
provided as part of the programme were funded through the Ministry of Health and 
delivered in local hospitals and primary healthcare facilities. Standard medications and 
diagnostics for pharyngitis, ARF, and RHD were employed. Health information was managed 
mainly by means of dedicated ARF registers at the provincial teaching hospital and 6 local 
hospitals. The study did not provide detailed information on systems of (clinical) care 
delivery but did describe novel healthcare worker and public education campaigns which 
were intended to increase demand for primary and secondary prevention services. 
Ralph and colleagues conducted a secondary prevention programme to promote the 
implementation of national ARF and RHD management guidelines in Australia.[18] Six 
primary health care clinics in Aboriginal communities of the Northern Territory (NT) region 
took part. A project management committee was established comprising the lead project 
investigators, health service managers, clinicians, staff of the NT RHD Control Program, and 
staff of RHD Australia. The 3-year project was financed by The National Heart Foundation 
of Australia, UNICEF Australia Health and the NT Department of Health and Community 
Services. A continuous quality improvement (CQI) intervention was implemented at the 
clinics to facilitate the use of the national best-practice ARF/RHD guidelines. The CQI 
method included two essential components: an RHD clinical audit tool for data collection 
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from clinical records, and the ABCD Systems Assessment Tool (SAT) to assess the clinic 
systems through discussions with health centre staff about the strengths and weaknesses of 
their health centre. The CQI was continually revised and improved and annual assessment of 
ARF/RHD health services were performed. 
Kwan and colleagues performed a cross-sectional analysis on a tertiary care programme.[19] 
The heart failure programme was embedded into existing non-communicable disease (NCD) 
clinics of two rural hospitals in Rwanda and was supported by Rwanda’s Ministry of Health 
as well as the non-governmental organisation Partners in Health. The government- 
subsidised health insurance covered services and medication with modest co-payments 
charged to individual patients. Further funding from Partners in Health protected patients 
from health care related out-of-pocket expenses and provided a transportation allowance. 
One day per week was dedicated to heart failure patient care at the NCD clinics. Each clinic 
team included 2 nurses and 2 administrative personnel, supervised by generalist physicians. 
Nurses underwent specialised training on ECG and algorithms for the diagnosis and 
management of heart failure. The cause of heart failure was determined following a physical 
examination and basic echocardiography; diagnosis was guided by pre-defined criteria. 
Following a diagnosis, each patient would receive a therapeutic plan, 6-week follow ups by 
nurses, and social support if necessary. Medication was administered daily and directly 
observed by a community health worker to ensure compliance. The exact diagnostic 
guideline used for RHD was unclear, but patients were treated with penicillin prophylaxis. 
3.3 Extent of Integration 
 
Table 2 describes the extent (fully, partially, not, unknown) and nature (type of health 
system function) of integration for the RHD prevention and control programmes included in 
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this study. The composite programme integration score was similar across all of the studies 
(either 9 or 10 out of 18), meaning that none of the programmes were completely 
integrated into the health system across all key functions. 
Financing was most often partially, if not fully, integrated across all of the programmes. 
Funds which did not come from the general health budget were supplemented by external 
organisations (such as AGFUND) but were channeled through the health system. Service 
delivery and demand generation were the second most integrated health system functions. 
The service delivery model employed by primary and secondary programmes were similar, 
where prophylaxis was administered in primary health care settings together with other 
health services, while case-finding efforts were more targeted. Similarly, demand 
generation was often executed separate from other health education activities (i.e., 
dedicated campaigns on RHD) but undertaken as part of the local government activities. 
Stewardship and governance was either partially or not integrated. Ministries of Health 
contributed to the governance of several programmes, but often accountability lay solely 
with a dedicated entity (either within the ministry or within an academic medical 
institution). Programme planning and monitoring and evaluation were almost never 
integrated into the health system among these programmes. Public health sector 
employees were usually involved in planning, but decision-making appeared to focus on 
RHD alone and did not consider other aspects of the health system or other diseases. There 
were insufficient details about stewardship and governance and programme planning for 
the Rwandan tertiary care intervention. Monitoring and evaluation was not well described 




Table 2: The extent and nature of integration by level of prevention for rheumatic heart disease programmes in various countries. 
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3.4 Programme Performance: Outputs, Outcomes and Impact 
 
Each study reported on slightly different programme outcomes; only the Cuban study 
presented evidence of the impact of their programme on disease endpoints (incidence, 
prevalence, and mortality) (Table 3). The primary and secondary programmes in Cuba 
resulted in fewer recurrent and first ARF attacks, and there was an overall decline in the 
prevalence of ARF and RHD. The severity of RHD was also controlled with fewer patients 
requiring hospitalization.[16] In Australia’s Northern Territory, there was a statistically 
significant improvement in the details documented on ARF and RHD patients, but the 
overall proportion of patients receiving ≥80% of scheduled BPG did not improve.[18] The 
programme in India successfully improved the ARF and RHD case detection rate in a high- 
risk community (from 7.8 cases per 100 000/year to 27.5 cases per 100 000/year), and 
registered patients maintained an 85-95% secondary prophylaxis compliance.[15] The 
average rate of prophylaxis coverage was 70% in the RHD programme implemented by 
WHO in multiple countries.[17] The tertiary care clinic in Rwanda saw 61 patients with 






















Table 3: Programme performance 
Country 
(Study ID) 





 Increased medical awareness among 
young patients. 
 Timely diagnosis and treatment of strep-throats.  The incidence of first ARF attacks 
declined from 12.2 per 100 000 in 1986 




 The number of clinical records audited 
each year were 154 in 2008, 145 in 
2009, and 156 in 2010. 
 The proportion of patients receiving 
BPG increased from 81/116 (70%) at baseline to 84/103 
(82%) in year three, p = 0.04. 
 The proportion of people receiving ≥80% of scheduled BPG 
did not improve, remaining around 25% across all six health 
centres over the study duration. 
 More patients were reviewed by their doctor within the 
past two years: from, 112/154 (73%) to 134/156 (86%), p = 
0.003. 
 Improved details on patients with ARF/RHD: ARF episode 
documentation increased from 31/55 (56%) to 50/62 (81%) 
(p=0.004), and RHD risk category documentation from 
87/154 (56%) to 103/145 (76%) (p < 0.001). 
 Patients within the recommended INR range increased 
from 64% to 75%. 




 327 patients registered over the study 
period. 
 Increased regular secondary prophylaxis compliance of 
registered patents (from 50% in 1986 to 93.8% in1996). 
 86.1% decline in the cost of managing the disease. 
 Decline in the prevalence of ARF and RHD 
(8.0 to 2.0 cases per 1 000 school children). 
 Decline in the incidence of recurrent 
attacks of ARF (6.4 to 0.4 per 100 000). 
 Decreased severity of RHD (5 cases of 
severe RHD in 1986 to only 1 in 1996) 
 Decrease in the number and of patients 
requiring hospitalization after the acute 
attack (from 41.1% of the 134 registered 
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   cases during 1986-90 to 8.3% of the 193 




 A total of 254 suspected cases of ARF 
or RHD referred by teachers, health 
workers, and medical officers. 
 The diagnosis and registration of 77 
new cases of ARF/RHD (of which 61 
were subsequently confirmed to have 
the disease). 
 3.5 time increases in the case detection rate in 
the intervention block (7.8/100 000/year to 
27.5/100 000/year). 
 95% compliance to secondary prophylaxis in the first6 
months, this declined to 85% after 2 years. 




 33 651 total patients identified and 
registered. 
 95.7% of patients received BPG 
injections, 2.1% oral penicillin, 0.1% 
sulfadiazine, and 2.1% erythromycin. 
 36 patients had an adverse reaction to 
BPG (0.3% patient-years), of whom 4 
died. 
 The rate of average prophylaxis coverage was 70%. 
 The rate of coverage per 100 patients registered per month 
averaged 63.2% (range, 23.8-96.9%). 
 Reoccurrence of ARF occurred in 53 patients (0.4%patient- 
years), of whom only 2 were receiving regular BPG. 
 Although it is stated that the reoccurrence 
rate of ARF decreased, no evidence was 
presented. 
Tertiary care    
Rwanda 
(Kwan 2013)[19] 
 192 patients were confirmed to have 
heart failure and were enrolled at the 
clinic. Of this cohort, 61 patients (32%) 
had RHD (26 patients were below the 
age of 18 years and 35 patients were 
adults). 
 Over the course of 4.4 years, the mean 
time spent in care was 19 months. The 
median time in care for alive patients 
with complete records (n=169) was 13 
months for children and 20 months for 
adults. 
 The observed retention in the programme was 62%. Fifty- 
five patients (29%) were lost to follow-up. 
 18 patients (9%) died, of which 3 had RHD. Mortality might 
be underestimated due to those lost to follow-up. 
 Not reported 
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3.5 Quantitative Analysis 
 
 
3.5.1 Acute Rheumatic Fever and Rheumatic Heart Disease-Related Outcomes 
Overall, programmes that are at least partially integrated in several dimensions appear to 
have a positive effect on clinical outcomes (Figure 2A). Specifically, improvements in the 
following outcomes were documented: incidence of first ARF attacks (RR, 0.08 [95% CI, 0.02 
to 0.33]), recurrent ARF attacks (RR, 0.22 [95% CI, 0.07 to 0.76]), hospitalization rates 
following an acute AFR attack (RR, 0.22 [95% CI, 0.00 to 0.15]), rates of severe RHD (RR, 0.05 
[95% CI, 0.01 to 0.45]), prevalence of ARF and RHD (RR, 0.24 [95% CI, 0.16 to 0.36]), and 
patients out of INR range (RR, 0.70 [95% CI, 0.23 to 2.11]). All of the outcomes were 
statistically significant, except for patients out of INR range which contains the null value of 
one in the 95% confidence interval. 
 
Figure 2A: The effect of an integrated AFR/RHD programme on ARF/RHD-related outcomes. 
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3.5.2 Acute Rheumatic Fever Secondary Prophylaxis Compliance 
 
Data on secondary prophylaxis were amenable to meta-analysis. Secondary prophylaxis 
compliance was defined in three studies as the probability of a patient receiving ≥80% 
of administered prophylaxis on a regular basis. There was a significant improvement in 
secondary prophylaxis compliance (RR, 1.18 [95% CI, 1.03 to 1.36], 3 studies, n=618) 








3.6 Risk of Bias 
 
The risk of bias assessment is presented in Table 4. Overall, two studies were found to have 
a low risk of bias while the remaining three studies were unclear. In two of the studies, it 
was unclear whether the outcome measure was accurately measured to minimise bias. One 
study inadequately described their method of cohort recruitment. 
Figure 2B: The effect of an integrated programme on ARF secondary prophylaxis compliance. 
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Table 4: Risk of bias assessment using the CASP tool [14] 











































1. Did the trial address a clearly focused issue? Y Y Y Y Y 
2. Was the cohort recruited in an acceptable way? Y Y Y Unclear Y 
3. Was the exposure accurately measured to minimise 
bias? 
n/a n/a n/a n/a n/a 
4. Was the outcome accurately measured to minimise 
bias? 
Y Y Unclear Y Unclear 
5. a. Have the authors identified all important 
confounding factors? 
b. Have they taken account of the confounding 











6. a. Was the follow up of subjects complete enough? 
b. was the follow up of subjects long enough? 
Y Y n/a n/a n/a 






4.1 Principal Findings 
 
This systematic review provides the first structured assessment of the extent of integration 
of RHD programmes into country health systems. We also collected information on 
programme inputs, activities, outputs, outcomes, and impact, but due to the limitations in 
the designs of the included studies we were not able to assess the association between 
programme design, programme integration, and population health outcomes. While most of 
the RHD programmes specified different outcomes, each demonstrated improved outcomes 
following programme implementation. 
A meta-analysis of secondary prophylaxis adherence showed a statistically significant 18% 
improvement in adherence (p=0.02) following the introduction of integrated RHD 
programmes in Cuba, India, and Australia. The programmes in Cuba and India both had an 
education component which targeted healthcare personnel, while in India this was 
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expanded to teachers and pupils. Both programmes also established a dedicated register to 
monitor patients with ARF and RHD and to administer prophylaxis. In contrast, the 
programme in Australia focused on improving clinical practice when diagnosing and 
managing patients with heart failure, including RHD. Therefore, there appears to be multiple 
channels for improving prophylaxis compliance which may include education about the 
disease, a register, or improved implementation of local ARF/RHD guidelines. 
None of the programmes were fully integrated, but they did share similarities in the nature 
and extent of integration into the local health system. The public sector usually took primary 
responsibility for financing of programmes and for providing clinical care itself, but planning 
of the RHD programme was never coordinated with the planning of other disease 
programmes or general health services. Monitoring and evaluation was also not integrated 
into existing health systems, and demand generation (understood to mean education of at- 
risk populations) was usually accomplished using a partially integrated approach. The results 
of this study are in agreement with a similar review which examined the extent and nature 
of integration for a number of other disease programmes, and found a heterogeneous 
picture of integration according to the critical health systems functions.[20] 
4.2 Strengths and Limitations of the Review 
 
The main strength of this review is that it provides a unique and comprehensive analysis of 
programme integration into the health systems while also providing the details of each 
programmes inputs, activities, outputs and outcomes. This makes the review relevant to the 
global agenda of scaling up RHD prevention and care initiatives. 
There are a number of limitations of this review. Firstly, there were date and English 
language restrictions on the searches which may have limited the number of publications 
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found. Secondly, the small number of included studies and the heterogeneity among their 
outcomes meant that sub-group analysis was not possible. Therefore, explanations cannot 
be made concerning the effect of integrating the programme according to critical health 
system functions. It should also be noted that three of the included studies draw from the 
same overall WHO-developed approach; they all included elements of health education and 
secondary prophylaxis. It is unclear whether there were overlapping patients studied. In 
particular, the study by Iyengar in India was conducted at the same time as the WHO multi- 
country programme (in which India was a participating country). 
4.3 Strengths and Limitations in Relation to Other Studies 
 
The findings of this review provide a new synthesis of evidence for the debate on RHD 
programme implementation. Compared to a prior systematic review of control programmes 
for communicable, maternal, perinatal, and nutritional diseases, our review found very few 
published studies on RHD prevention and control programmes.[20] 
4.4 Explanations and Implications for Clinicians and Policymakers 
 
The 2018 World Health Assembly resolution on ARF and RHD is indicative of the important 
health problem RHD poses in many countries; however, there is currently limited evidence 
for designing efficient programmes to scale up evidence-based interventions. Further, 
governments are being encouraged to use more horizontal, integrated approaches when 
designing health programmes.[7] Health planners need reliable evidence upon which to 
design and implement new RHD initiatives in a manner that is sustainable and synergistic 
with other health system activities. 
Based on existing evidence, we can identify the following best practices across the six key 
health system functions. The most effective RHD programmes employ stewardship and 
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governance models that involve a dedicated unit, for example within a subnational ministry 
of health office, which is responsible and accountable specifically for RHD. Financing of RHD 
prevention and treatment interventions should be integrated with general health system 
resources; external donors wishing to invest in RHD should channel funds through Ministries 
of Health to ensure efficient purchasing and strengthening of local systems. In the published 
literature RHD programme planning has not been integrated with planning for other priority 
health issues; however, it is unlikely that this approach will be desirable in the future, 
especially for complex and comprehensive RHD programmes that include a variety of 
activities ranging from primary prevention to surgery. Published models of care indicate that 
service delivery is best accomplished through the general primary healthcare system, 
although targeted case-finding activities may be appropriate in some settings, and when 
these have been conducted in the past, they have made use of dedicated outreach 
healthcare workers. As mentioned, monitoring and evaluation of RHD programmes has 
typically not been integrated, and it is not clear how information systems for ARF and RHD 
should interact with the rest of the health system (since non-integrated registers, for 
example, may result in superior patient outcomes). Finally, demand generation – 
understood in this context to mean information, education, and communication – has 
usually been only partially integrated, such as through dedicated media campaigns and 
specialised educational activities. 
The partially integrated nature of published RHD programmes fits well with the observation 
that endemic infectious diseases with “elimination” potential may be best addressed 
eventually through more targeted activities that, as disease incidence declines, can be 
gradually integrated into the general primary healthcare system.[21] In this way, RHD stands 
out from other NCDs, for which there is consensus that vertical approaches are 
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inappropriate.[22] Decision-makers and planners may benefit from thinking about RHD 
programmes through an infectious disease and elimination framework rather than through 
a chronic disease framework. This may especially be the case in low-income countries where 
resources will initially be devoted to primary and secondary prevention rather than cardiac 
surgery.[23] 
4.5 Future Research 
 
The findings of this review provide a starting point for the design and implementation of 
RHD programmes, but they also highlight some major gaps in knowledge, including a lack of 
clear evidence on the key programme factors that facilitate integration and still deliver good 
outcomes. For example, it is recommended that monitoring and evaluation of ARF/RHD 
secondary prevention activities make use of disease registers. There is no evidence that 
countries have taken disease registers to scale, and existing reports suggest that such 
registers have not been integrated into general health information and surveillance systems. 
Further investigation is required into whether these registers would be more effective if they 
were integrated into health information systems, or rather as parallel information systems. 
Comparative research, using prospective quasi-experimental and experimental methods, is 
needed in order to determine how to optimise the effectiveness of RHD-related health 
technologies while moving towards fully integrated programme models. Future research 
should report on the impact of the programme, namely the incidence, prevalence, or 
mortality, as standard reporting practice. It is also imperative that the local socio-cultural 
context is seriously considered when designing future RHD prevention and control 
interventions so that a local evidence-base can be built to directly advise the decision 




We present a systematic analysis of RHD prevention and control programmes and their 
integration into a various country health systems. The programmes presented in this review 
were partially integrated, similar in the extent and nature of integration, and appear to be 
beneficial for RHD-related outcomes. While this research provides a starting point for future 
RHD programme implementation according to the six key health system functions, it also 
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APPENDIX 1: PRISMA 2009 Checklist (Manuscript) 
 




Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 
ABSTRACT  
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number. 
 
1 - 2 
INTRODUCTION  
Rationale 3 Describe the rationale for the review in the context of what is already known. 4 - 5 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). 
5 
METHODS  
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number. 
5 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale. 
5 – 6 
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched. 
5 – 6 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. Appendix 2 
2  
 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis). 
6 
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators. 
 
6 – 7 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made. 
7 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study 
or outcome level), and how this information is to be used in any data synthesis. 
7 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 7 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis. 
7 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies). 
7 




RESULTS    
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram. 
8 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations. 
 
9 – 11 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 22 – 23 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot. 
12 – 14 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 22 – 23 
3  
 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 21 – 22 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). n/a 
DISCUSSION    
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers). 
23 – 24 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias). 
 
24 – 25 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 25 - 28 
FUNDING    




From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097 
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APPENDIX 2: Comprehensive Search Strategy 
 
 Subject Search Terms 
PubMed search strategy 
#1 Group A Streptococcus, 
rheumatic fever, 
rheumatic heart disease 
Pharyngitis[MeSH Terms] OR rheumatic heart disease[MeSH Terms] OR rheumatic 
fever[MeSH Terms] OR pharyng*[Title/Abstract] OR "sore throat"[Title/Abstract] 
OR "group A strep*"[Title/Abstract] OR "rheumatic fever"[Title/Abstract] OR 
"rheumatic heart disease"[Title/Abstract] OR RHD[Title/Abstract] 
#2 Health service delivery (preventative health services[MeSH Terms]) OR delivery of health care, 
integrated[MeSH Terms]) OR healthcare[Title/Abstract]) OR health 
care[Title/Abstract]) AND (vertical[Title/Abstract] OR horizontal[Title/Abstract] OR 
integrated[Title/Abstract] OR coordinat*[Title/Abstract] OR co- 
ordinat*[Title/Abstract] OR program*[Title/Abstract] OR service*[Title/Abstract]) 
Search  1 AND 2 
Filters: Publication date from 1 January 1990 to 31 December 2017. 
  Scopus  
#1 Group A Streptococcus, 
rheumatic fever, 
rheumatic heart disease 
( TITLE-ABS-KEY ( pharyngitis )  OR  TITLE-ABS-KEY ( "rheumatic fever" ) OR TITLE- 
ABS-KEY ( "rheumatic heart disease")  OR  TITLE-ABS-KEY ( "sore 
throat" ) OR TITLE-ABS-KEY ( "group A strep*" ) OR   TITLE-ABS-KEY ( rhd ) ) 
#2 Health service delivery ( ( TITLE-ABS-KEY ( delivery )  OR TITLE-ABS-KEY ( integrated ) OR  TITLE-ABS- 
KEY ( program* ) OR TITLE-ABS-KEY ( programme*) OR TITLE-ABS- 
KEY ( service*)  OR  TITLE-ABS-KEY (horizontal)  OR TITLE-ABS- 
KEY (vertical) ) ) AND ( (TITLE-ABS-KEY (health AND care) OR TITLE-ABS- 
KEY (healthcare) ) ) 
Search  1 AND 2 
Filters: Publication date from 1 January 1990 to 31 December 2017. 
  EBSCO Host (Africa Wide, CINAHL, and Health Source: Nursing/Academic Edition)  
#1 Group A Streptococcus, 
rheumatic fever, 
rheumatic heart disease 
AB "rheumatic heart disease" OR AB "rheumatic fever" OR AB "group A strep*" OR 
AB pharyng* OR AB "sore throat" 
#2 Health service delivery AB delivery of health care, integrated OR AB health care OR AB healthcare AND AB 
vertical OR AB horizontal OR AB integrated OR AB coordinat* OR AB co-ordinat* 
OR AB program* OR AB service* 
Search  1 AND 2 
Filters: Publication date from 1 January 1990 to 31 December 2017. 
  ISI Web of Science  
1 Group A Streptococcus, 
rheumatic fever, 
rheumatic heart disease 
TOPIC: ("rheumatic heart disease") OR TOPIC: ("rheumatic 
fever") OR TOPIC: ("group A strep*") OR TOPIC: (pharyng*) OR TOPIC: ("sore 
throat") 
2 Health service delivery (health care) OR TOPIC: (heath care) AND 
TOPIC: (vertical) OR TOPIC: (horizontal) OR TOPIC: (coordinat*) OR TOPIC: (co- 
ordinat*) OR TOPIC: (integrated) OR TOPIC: (program*) OR TOPIC:(service*) 
Search  1 AND 2 
Filters: Publication date from 1 January 1990 to 31 December 2017. 
5  
APPENDIX 3: Data Extraction Form 
 
A. General Information 
 
Date form completed 
(dd/mm/yyyy) 
 
Name of data extractor  
Reference citation  
Study author contact details  
Publication type 
(e.g. full report, abstract) 
 
Potentially eligible studies 




B. Eligibility criteria 
Study characteristics Eligibility criteria (circle) Criteria met? 
Type of study RCT, CCT, CBA, ITS, quasi-experimental, cross- 
sectional. 
Yes No Unclear 
Intervention A coherent and intentional effort to expand 
health services to the population at risk for GAS, 
RF, RHD 
Yes No Unclear 
Types of outcome measures 
Include studies providing 
sufficient info on objectives 
#1 and #2. 
The secondary outcome #3 
does not have to be met but 
should be recorded so that 
we can report the % of 
studies that does meet #3. 
1. Programme characteristics 
Programme start year, location(s), duration, area 
of emphasis (services delivered), inputs 
Yes No Unclear 
2. Programme integration 
6 key functions of the health system (stewardship 
& governance, financing, planning, service 
delivery, M&E, demand generation) 
Yes No Unclear 
3. Programme results 
Outputs (volume and scope of services produced) 
and outcomes (such as time in therapeutic INR 
range, adherence to secondary prophylaxis, or 
proportion of the population covered) 
Yes No Unclear 





DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
Study ID (first author surname and year of publication e.g. Atun, 2009) 
6  
C. Characteristics of included studies 
 Description as stated in the paper/report 
Objective(s) of study  
Brief description of intervention(s) 
or model(s) studied 
 
Study design  
Country, province/state (if known)  
Notes: 
 
D. Outcome measures 
I. Programme characteristics 
 
Description as stated in the paper/report 
Start year 
Duration (recruitment – last follow- 
up) 
Number of patients seen in the 
programme 
Primary prevention component? 
Yes No Unclear 
If yes, provide details: 
Secondary prevention component? 
Yes No Unclear 
If yes, provide details: 
Tertiary prevention component? 
Yes No Unclear 
If yes, provide details 
Inputs 
(Organised according to WHO 
“building blocks” framework) 
 
When possible, provide 
quantitative data, e.g., budget of 
US$ 100,000 per year; 30 nurses 




Financing - source(s) and amount(s): 
Unclear/not stated 
Healthcare workers (types and numbers): 
Unclear/not stated 
Technologies (drugs, diagnostics, etc.) 
Unclear/not stated 









II. Extent of programme integration 
Critical health system function 
(Elements) 
Extent of integration 
Stewardship & Governance 
(Accountability function; reporting; 
performance management) 
Fully Partially Not integrated Unknown 
Notes: 
Financing 
(Pooling of funds; provider payment 
methods) 
Fully Partially Not integrated Unknown 
Notes: 
Planning 
(needs assessment; priority setting; 
resource allocation) 
Fully Partially Not integrated Unknown 
Notes: 
Service delivery 
(Structural; human resources; 
shared infrastructure; operational 
integration; referral and counter- 
referral systems; guidelines or care 
pathways; procurement; supply 
chain management) 
Fully Partially Not integrated Unknown 
Notes: 
Monitoring and evaluation 
(Information technology 
infrastructure; data collection and 
analysis) 
Fully Partially Not integrated Unknown 
Notes: 
Demand generation 
(Financial incentives e.g. 
conditional cash transfers, 
insurance; populationinterventions 
e.g. education and promotion) 




III. Programme results 
 Description as stated in the paper/report 
Outputs (goods and services produced and delivered) – quantify when possible 
8  
Primary prevention component  
Secondary prevention component  
Tertiary prevention component  
Outcomes (use of outputs by targeted population) – quantify when possible 
Primary prevention component  
Secondary prevention component  
Tertiary prevention component  
Impact (change in health of targeted population) – experimental and quasi-experimental designs only 
Primary prevention component  
Secondary prevention component  
Tertiary prevention component  
 
 
E. Risk of bias assessment 





Are the results of the trial valid?   
7. Did the trial address a clearly focused issue?   
8. Was the cohort recruited in an acceptable way?   
9. Was the exposure accurately measured to minimisebias?   
10.  Was the outcome accurately measured to minimise bias?   
11. a. Have the authors identified all important confounding factors? 
b. Have they taken account of the confounding factors in the design 
and/or analysis? 
  
12.  a. Was the follow up of subjects complete enough? 
b. was the follow up of subjects long enough? 
  
What are the results?   
13.  What are the results of the study?   
14.  How precise are the results?   
15.  Do you believe the results?   
Will the results help locally?   
16.  Can the results be applied to the local population?   
17.  Do the results fit with other available evidence?   
18. What are the implications of this study for practice?   
 
 






Are the results of the trial valid?   
19.  Did the study address a clearly focused issue?   
20.  Was the assignment of patients to treatments randomised?   
21. Were all of the patients who entered the trial properly accounted 
for at its conclusion? 
  
22. Were patients, health workers and study personnel ‘blind’ to 
treatment? 
  
23.  Were the groups similar at the start of the trial?   
24. Aside from the experimental intervention, were the groups treated 
equally? 
  
What are the results?   
25.  How large was the treatment effect?   
26.  How precise was the estimate of the treatment effect?   
Will the results help locally?   
27. Can the results be applied in your context/to the local population?   
28.  Were all clinically important outcomes considered?   
29.  Are the benefits worth the harms and costs?   
10  
APPENDIX 4: Criteria for Determining the Extent of Integration for each Health System 
Function 
 
Fully integrated (score = 3) Partially integrated (score = 2) Not integrated (score = 1) 
Stewardship and 
Governance 
Oversight and guidance. 
When the governance 
arrangements for the 
intervention are the same 
as those for the general 
health services or the local 
or national administrative 
structures. 
The responsibility is shared by 
the existing general health care 
system and a specific structure 
created purposely for the 
intervention. 
When accountability remains 
exclusively with dedicated 
specialist entities charged 
with implementation and 
management of health 
interventions, without 
involvement of the general 
health care system. 
Financing 
The pooling of financial 
resources and the 
provider-payment 
methods used to allocate 
these. 
Funding is provided entirely 
through the national or 
regional general health care 
budget. 
For example, where earmarked 
funding was provided by the 
United States Agency for 
International Development 
(USAID) but channelled 
through the PHC system. 
When financing is provided 
directly to an intervention 
and addressing only a 
particular disease or 
problem; or directly funded 
by an external donor. 
Planning 
Activities, processes and 
systems for needs 
assessment, priority 
setting, and resource 
allocation. 
If the decision-making in 
relation to the above three 
areas is undertaken by 
institutions/stakeholders 
who are involved in the 
same tasks for the general 
health system. 
Decision-making responsibility 
for planning is retained by 
those managing the health 
intervention but involves a 
range of stakeholders (such as 
civil society representatives, 
PHC level, or 
local/regional/national 
government) through inclusive 
When the decision-making 
focused solely on the 
intervention without 
consideration of general 
health care activities. This 
may include specific national 






dimensions of the 
programme. 
If their provision is the 
responsibility of general or 
multi-purpose health 
worker. 
Where there is shared 
responsibility for the provision 
of services between general 
health workers and the health 
intervention staff; purpose 
trained volunteers; when 
service delivery for a number 
of interventions is linked. 
A number of interventions 
rely solely on single purpose 
workers and have no 
integration with other 




Use of shared indicators and 
establishment of integrated 
data collection, recording, 
analysis and reporting 
systems. 
When M&E were undertaken 
jointly by staff from the 
regional health services and 
the control programme. 
When M&E is undertaken 
independently by the 
sponsor, institution, or 
volunteers of the 
implementing organisation. 
Demand generation 
The use of appropriate 





activities designed to 
change behaviour. 
If mechanisms used to 
create financial incentives 
or education and 
communication activities 
are provided jointly with the 
general services or are 
delivered by primary health 
care workers. 
When education is provided 
jointly by the targeted 
programme staff and regional 
health workers. 
Where information 
campaigns related to health 
interventions are stand- 
alone activities, focusing 
solely on a single problem or 
disease, and delivered by 
single-purpose health 
workers or volunteers. 
From: Atun R, de Jongh T, Secci F, et al. Integration of targeted health interventions into health systems: a conceptual 
framework for analysis. Health Policy Plan 2010;25:104–11.http://dx.doi.org/10.1093/heapol/czp055, and Atun R, de 
Jongh T, Secci F, et al. A systematic review of the evidence on integration of targeted health interventions into health 
systems. Health Policy Plan 2010;25:1–14.http://dx.doi.org/10.1093/heapol/czp053. 
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UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 




Room E53·48 Old Main Bulldlng 
Groote Schuur Ho1pltal 
Observatory 7925 




05 January 2017 
 





Dear A/Prof Engel 
Project Title: Integrating the prevention and control of rheumatic heart disease Into country 
health system: A systematic review 
Thank you for submitting your request to the Faculty of Health Sciences Human Research Ethics 
Committee. 
The HREC note that the proposed study Is a systematic review. 
As the systematic review involves published llterature available through publlcally accessible 
electronlc databases, research ethics review and approval is not required. 
This Is In accordance with Section 1.1.8 of the Department of Health's Ethics In Health Research: 
Principles, Processes and Structures (South African Department of Health, 2015), which states: 
"Research that relies exclusively on publicly available information or accessible through legislation or 
regulation usually need not undergo formal ethics review. This does not mean that ethical 
considerations are irrelevant to the research." 
The HREC recommend that researchers refer to the PRISMA website, for the PRISMA statement and 
checklist, to facilltate the reporting of systematic reviews and meta-analyses. For more information, 
please refer to http;//www.prlsma-statement,org/. 
Further, fundamental ethlcal prlnclples for health-related research should be considered In the 
objectives and methods of the systematic review. See, for example, the Declaratlon of Helsinki 
(Fortaleza, Brazil, 2013) and the Department of Health's Ethics In Health Research: Prlnclples, 
Processes and Structures (South African Department of Health, 2015). 
The HREC acknowledge that the student Ms Jessica Abrams (MPH Student: ABRJES009) wlll also be 





PROFESSOR M BLOCKMAN 
CHAIRPERSON. fHS HUMAN 
 
RESEARCH ETHICS COMMITTEE 
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Revised: 3 May 2018 1. PUBLISHING AT THE BMJ 
1.1 Publishing model 
The BMJ is an online publication and publishes its articles 
continuously to bmj.com. The website is updated daily with 
original articles, podcasts, videos, and blogs and organ- 
ised into four main content streams—research, education, 
news and views, and campaigns. In addition, the site is fully 
searchable, with an archive going back to 1840 and numer- 
ous topic collections on clinical and non—clinical   subjects. 
 
Some articles published online will subsequently also 
appear in a print issue of The BMJ. The print journal is 
now published in three editions: one weekly edition 
targeting hospital clinicians, primarily in the UK; a 
second weekly edition for GPs; and a third monthly 
edition aimed at academics and a more international 
audience. 
 
1.2 Acceptance rate and handling times 
We publish only about 7% of the 7000—8000 articles we 
receive each year (and only about 4% of the 4,000 research 
articles). We reject about two thirds of all submissions with- 
out sending them for external peer review, but many authors 
tell us they appreciate quick decisions that allow them to sub- 
mit their work elsewhere without delay. In 2016, the median 
time to make a first decision for research, analysis, and edu- 
cation papers sent out for review was 48, 83, and 31 days, 
respectively, with a 2 day initial screening time for research. 
 
1.3 Open access 
All research papers in The BMJ are published with open 
access. Moreover, The BMJ immediately fulfils the require- 
ments of the US National Institutes of Health, the UK Medi- 
cal Research Council, the Wellcome Trust, and other funding 
bodies by making the full text of publicly funded research 
freely available to all on bmj.com and sending it directly to 
PubMed Central, the National Library of Medicine’s full text 
 ABOUT THE BMJ  
Published without interruption since 1840, our mission is to lead the debate on 
health and to engage, inform, and stimulate doctors, researchers, and other health 
professionals in ways that will improve outcomes for patients. To achieve these 
aims we publish original research articles, review and educational articles, news, 
letters, investigative journalism, and articles commenting on the clinical, scientific, 
social, political, and economic factors affecting health that help doctors make 
better clinical, research and public health decisions. The BMJ also aims to publish 
articles that advance debate on the science and art of patient partnership and 
co—production of health. We are delighted to consider articles for publication from 
doctors and others, and from anywhere in the world. Although the editorial office is 
located in London, we have editors throughout the world, including Europe, North 
America, South Asia, and China. 
BMJ GUIDANCE FOR AUTHORS  
Publishing at The BMJ 
1.1 Publishing model 
1.2 Acceptance rate and handling times 
1.3 Open access 
Is The BMJ the right journal for my article? 
2.1 Article types at The BMJ 
Preparing your article 
3.1 Requirements for ALL manuscripts 
3.2 Title page and authorship 
3.3 Contributor and guarantor information 
3.4 Copyright/licence for publication 
3.5 Patient consent 
3.6 Competing interests declaration 
 
Additional requirements by article type 
4.1 Research 
4.1.1 What kind of research does The BMJ publish? 
4.1.2 Patient and public involvement, ethical policies 
4.2 Research Methods and Reporting (RMR) 
4.3 Analysis 
4.4 Education (including Minerva and Endgames) 
4.5 Editorials 
4.5 Personal Views/BMJ Opinion 
4.5 BMJ Careers 
4.5 Fillers and endpieces 
4.5 Obituaries 
 
Submission  and post-submission 
5.1 Submitting an article 
6.1 Rapid responses 
For personal use only 2 of 15  
 BMJ  
 
archive. The BMJ occasionally publishes as open access other 
types of (non—research) articles arising from work funded by 
a funder who mandates open access  publication. 
 
All Research articles published by The BMJ are published 
by default as open access (irrespective of who funded the 
research). Any other article based on work funded by a fund- 
ing organisation that requires open access publication—that 
is, requires its grant recipients to deposit publications arising 
out of the funded work to be deposited in PubMed Central 
open access repository - can also be published as such. We 
offer two types of open access license: 
 
• CC BY-NC — by default, we publish our Open Access 
articles under a Creative Commons Attribution Non 
Commercial  (CC  BY-NC  4.0).   CC   BY-NC   articles   allow  
the  author, and  any  non-commercial  bodies,   to   reuse 
the material in any way they choose, without acquiring 
permission from BMJ. Any reuse must give attribution to the 
author, usually by including a reference. Commercial users 
will require permission from BMJ for any reuse. 
 
CC BY-NC articles can be identified by the following state- 
ment that appears at the end of the article: 
“This is an open access article distributed in accordance with 
the Creative Commons Attribution Non Commercial (CC BY-NC 
 
 
4.0) license, which permits others to distribute, remix, adapt, 
build upon this work non-commercially, and license their 
derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// 
creativecommons.org/licenses/by-nc/4.0.” 
 
• CC BY — articles funded by certain organisations (currently 
RCUK and the Wellcome Trust) that mandate publication 
with a Creative Commons Attribution (CC BY 4.0) licence are 
published with this licence. CC BY 4.0 permits reuse for com- 
mercial purposes subject to the article being fully attributed 
 
CC BY articles can be identified by the following statement 
that appears at the end of the article: 
“This is an open access article distributed in accordance with 
the terms of the Creative Commons Attribution (CC BY 4.0) 
license, which permits others to distribute, remix, adapt and 
build upon this work, for commercial use, provided the origi- 
nal work is properly cited. See: http://creativecommons.org/ 
licenses/by/4.0.”For additional information, please see the 
section of instructions to authors on copyright, open access, 
and permission to  reuse. 
 
2. ARTICLE TYPES AT THE BMJ 
At The BMJ, we offer the opportunity to submit a range of 
article types, each with different requirements. Before sub- 
mitting any work to The BMJ, we encourage all authors to 
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is framed in the best possible way for review and publication. 
You can find out more about our main article type, as well 
as access examples of previously published articles in the 
table to the left. 
 
3. PREPARING YOUR ARTICLE 
3.1 Requirements for ALL manuscripts 
Please ensure that anything you submit to The BMJ conforms 
to the International Committee of Medical Journal Editors’ 
(ICMJE) Recommendations for the Conduct, Reporting, 
Editing, and Publication of Scholarly work in Medical 
Journals uniform recommendations for manuscripts sub- 
mitted to biomedical journals. Before submitting an article, 
please ensure that you have followed all guidelines below. 
 
Further details about The BMJ’s stance on authorship, con- 
tributorship and group authorship can be found on our 
Authorship and contributorship page. 
 
3.2 Title page and authorship 
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MEDLINE citation.” 
from us. Only if the use is commercial do we need to know 
about it. In addition, we will pay authors a royalty on certain 
commercial uses that we negotiate. 
Information on permissions for authors and third parties for 
reuse can be found here. 
 
Manuscripts authored or coauthored by one or more National 
   3.3 Contributor and guarantor information Institutes of Health (NIH) employees must be   submitted 
We strongly encourage all authors 
to register for an ORCID profile. To 





BMJ house style and image 
usage  guidelines  
Learn about our house writing 
style 
Find out more about incorporating 
images into your submission 
Contributorship statements should make clear who has 
contributed what to the planning, conduct, and reporting of 
the work described in the article, and should identify one, or 
occasionally more, contributor(s) as being responsible for the 
overall content as guarantor(s). The guarantor accepts full 
responsibility for the work and/or the conduct of the study, 
had access to the data, and controlled the decision to pub- 
lish. Specific contributions are determined by the authors 
themselves - we do not have a specific taxonomy on contri- 
butions. For articles in The BMJ that do not report original 
research — such as editorials, clinical reviews, and education 
and debate — please state who had the idea for the article, 
who performed the literature search, who wrote the article, 
with a completed and signed NIH Publishing Agreement 
and Manuscript Cover Sheet according to NIH’s Employee 
Procedures. 
 
3.5 Patient consent (if applicable) 
Publication of any personal information about a patient 
in The BMJ — for example, in a case report or clinical pho- 
tograph — will normally require the signed consent of the 
patient. If this is the case, please include a statement that 
any identifiable patients have provided their signed consent 
to publication and submit as a supplemental  file. 
 
3.6 Competing interests declaration 
   and who is the guarantor (the contributor who accepts full A competing interest — often called a conflict of interest — 
BMJ patient consent forms  
Our consent forms are available in 
multiple languages at this page. 
responsibility for the finished article, had access to any data, 
and controlled the decision to publish). For non—research 
articles that include case reports such as lessons of the week, 
drug points, and interactive case reports, please also state 
who identified and/or managed the case(s). We encourage 
authors to fully acknowledge the contribution of patients and 
the public to their research where appropriate. 
 
3.4 Copyright/licence for publication 
Since January 2000, The BMJ has not asked authors of 
journal articles to assign us their copyright and authors 
(or their employers) retain their copyright in the article. All 
we require from authors is an exclusive licence (or, from 
government employees who cannot grant this, a non— 
exclusive licence) that allows us to publish the article in 
The BMJ (including any derivative products) and any other 
BMJ products (such as overseas editions), and allows us  
to sublicence  such  rights  and exploit  all subsidiary rights. 
 
For non-research articles, we ask the corresponding author 
to grant this exclusive licence (or non—exclusive for govern- 
ment employees) on behalf of all authors by reading our 
licence and inserting in the manuscript on submission the 
following  statement: 
 
“The Corresponding Author has the right to grant on behalf of 
all authors and does grant on behalf of all authors, a world- 
wide licence to the Publishers and its licencees in perpetuity, 
in all forms, formats and media (whether known now or cre- 
ated in the future), to i) publish, reproduce, distribute, display 
and store the Contribution, ii) translate the Contribution into 
other languages, create adaptations, reprints, include within 
collections and create summaries, extracts and/or, abstracts of 
the Contribution, iii) create any other derivative work(s) based 
on the Contribution, iv) to exploit all subsidiary rights in the 
Contribution, v) the inclusion of electronic links from the Con- 
tribution to third party material where—ever it may be located; 
and, vi) licence any third party to do any or all of the above.” 
This licence allows authors to use their own articles for their 
own non—commercial purposes without seeking permission 
exists when professional judgment concerning a primary 
interest (such as patients’ welfare or the validity of research) 
may be influenced by a secondary interest (such as financial 
gain, academic promotion, or personal rivalry). It may arise 
for the authors of an article when they have a financial inter- 
est that may influence, probably without their knowing, their 
interpretation of their results or those of others. 
 
We believe that to make the best decision on how to deal 
with an article, we should know about any competing inter- 
ests that authors may have, and that if we publish the article 
readers should know about them too. We are not aiming to 
eradicate such interests across all article types in The BMJ. 
However, certain articles (see below) fall under a stricter 
policy announced in 2014. This means that authors whose 
financial conflicts of interest are judged to be relevant by 
the BMJ team are not permitted to write these articles. We 
also ask our staff and reviewers to declare any competing 
interests. 
 
A declaration of interests for all authors must be received 
before an article can be reviewed and accepted for pub- 
lication. It should take one of two forms, depending on 
what type of article you are submitting, detailed on the 
following page. 
 
4. ADDITIONAL REQUIREMENTS BY ARTICLE TYPE 
In addition to the above, all of our articles have additional 
requirements which should be fulfilled before submitting. 
For more information on any of the requirements below, 
please contact papersadmin@bmj.com. 
 
4.1 RESEARCH 
4.1.1 What kind of research does The BMJ publish? 
The BMJ gives priority to articles reporting original, 
robust research studies that can improve decision making 
in medical practice, policy, education, or future research 
and will be important to general medical readers inter- 
nationally. 
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Research and RMR 
articles 
Since 2014, The BMJ requires that such articles must be written by authors without 
relevant financial ties to industry. By “industry” we mean companies producing drugs, 
medical foods, nutraceuticals, devices, apps or tests; medical education companies; or other 
companies with a financial or reputational interest in the topic of the article. We consider the 
following relationships with industry to be relevant, making it unlikely that we would be able to 
publish your work: employment; ownership of stocks and shares (this excludes mutual funds 
or other situations in which the person is not in a position to control investment decisions) ; 
travel and accommodation expenses; paid consultancy or directorship; patent ownership; aid 
membership of speakers’ panels or bureaus and advisory board; acting as an expert witness 
; being in receipt of a fellowship, equipment, writing, or administrative support; writing or 
consulting for a medical education promotional or communications company. If you are in 
doubt about the relevance of any potential conflict of interest please discuss with the editor of 
the appropriate section before submission. 
 
All authors must review the updated COI policy and complete The BMJ’s Education 
Declaration of Interests form. If the article is accepted for publication these completed forms 
will be stored and made available on request. The corresponding author should insert within 
their manuscript a summary statement derived from the information provided in the COI 
forms (link below): “I/We have read and understood BMJ policy on declaration of interests and 
declare the following interests: [list them or state that you have none].” 
We ask authors of research papers to use a revised version of the ICMJE’s unified disclosure 
form. The unified form can be used for several journals. Each journal, will, however, integrate 
the form into its processes in different ways. 
Authors must disclose three types of information: 
• Associations with commercial entities that provided support for the work reported in 
the submitted manuscript (the timeframe for disclosure in this section of the form is the 
lifespan of the work being reported). 
• Associations with commercial entities that could be viewed as having an interest in the 
general area of the submitted manuscript (in the three years before submission of the 
manuscript). 
• Non—financial associations that may be relevant or seen as relevant to the submitted 
manuscript. 
All authors must complete the disclosure form and send it to the corresponding author 
who will use the information in the forms to craft the COI statement for the paper (examples 
provided below). The statement but not the forms must be included with the submission. and 
that must be included with the initial submission. If the paper is accepted, these forms will be 
required and will be published alongside the article. 
The statement in the manuscript should take the following format: 
“Competing interests: All authors have completed the ICMJE uniform disclosure form at 
www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the 
submitted work [or describe if any]; no financial relationships with any organisations that 
might have an interest in the submitted work in the previous three years [or describe if any]; no 
other relationships or activities that could appear to have influenced the submitted work [or 
describe if any].” 
• No competing interests: “We have read and understood BMJ policy 
on declaration of interests and declare that we have no competing 
interests.” 
• Competing interests disclosed: “We have read and understood BMJ 
policy on declaration of interests and declare the following interests: AA 











• No competing interests: “All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no 
support from any organisation for the submitted work; no financial 
relationships with any organisations that might have an interest in the 
submitted work in the previous three years; no other relationships or 
activities that could appear to have influenced the submitted work.” 
• Grant funding for research but no other competing interest: “All authors 
have completed the ICMJE uniform disclosure form at www.icmje.org/ 
coi_disclosure.pdf and declare: all authors had financial support from 
ABC Company for the submitted work; no financial relationships with 
any organisations that might have an interest in the submitted work in 
the previous three years; no other relationships or activities that could 
appear to have influenced the submitted work.” 
• Mixed competing interests: “All authors have completed the ICMJE 
uniform disclosure form at www.icmje.org/coi_disclosure.pdf and 
declare: no support from any organisation for the submitted work; AB 
has received research grants and honorariums from XYZ company, BF 
has been paid for developing and delivering educational presentations 
for BBB foundation, DF does consultancy for HHH and VVV companies; 
no other relationships or activities that could appear to have influenced 
the submitted work.” 
All other articles Complete The BMJ’s Disclosure form. We do not need to receive signed copies of the statements regarding competing interests or the licence to publication: these are for 
information only. When submitting your article (or a revised version of it) you will be prompted at our online editorial office to tick two boxes , confirming that you have read and 
complied with our policies on competing interests and licence to publication. Please also ensure that your manuscript, whether in original or revised form, also includes your 
written statements of competing interests and licence to publication. 
The BMJ welcomes studies that will aid the translation of 
knowledge and implementation of evidence into practice 
and policy, and is particularly interested in evaluations 
of the comparative effectiveness of interventions. This 
knowledge may be most relevant to the day to day deci- 
sions doctors make with patients, to public health, or to 
policy decisions about  healthcare. 
To learn more about the kind of research articles we 
give priority to, and what services we offer to authors 
of research, please read the editorial “Publishing your 
research study in the BMJ?”. Please note that we wel- 
come studies — even with “negative” results — as long 
as their research questions are important, new, and rel- 
evant to general readers and their designs are appropri- 
ate and robust. 
 
Word count and style 
To encourage full and transparent reporting of research we 
do not set fixed word count limits for research articles. None- 
theless, we ask you to make your article concise and make 
every word count. You will be prompted to provide the word 
count for the main text (excluding the abstract, references, 
tables, boxes, or figures) when you submit your manuscript. 
 
Original research articles should follow the IMRaD style 
(introduction, methods, results, and discussion) and should 
include a structured abstract (see below), a structured dis- 
cussion, and a succinct introduction that focuses — in no 
more than three paragraphs — on the background to the 
research question. 
 
For an intervention study, the manuscript should include 
enough information about the intervention(s) and 
comparator(s) (even if this was usual care) for reviewers 
and  readers   to   understand   fully   what   happened   in 
the study. To enable readers to replicate your work or 
implement  the  interventions  in  their  own   practice, 
please  also  provide  any  relevant  detailed  descriptions 
and materials (uploaded as one or more supplemental 
files, including video and audio files where appropriate). 
Alternatively, please provide URLs to openly accessible 
websites where these materials can be found. 
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Please ensure that the discussion section of your article 
comprises no more than a page and a half and follows this 
overall structure, with subheadings: 
 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Strengths and weaknesses in relation to other studies, 
discussing important differences in results 
• Meaning of the study: possible explanations and 
implications for clinicians and  policymakers 
• Unanswered questions and future research 
 
Structured abstract 
Please ensure that the structured abstract is as complete, 
accurate,  and clear  as possible  and has been approved   by 
   all  authors.  We  may  screen  original  research  articles    by 
 
avoid “we  did”  or  “we  found”.   Numbers   over   10   do 
not need spelling out at the start of sentences. P values 
should always be accompanied by supporting data, and 
denominators should be given for percentages. Confidence 
intervals should be written in the format (15 to 27) within 
parentheses, using the word “to” rather than a hyphen. 
Abstracts do not need references. 
 
Statistical issues 
We want your piece to be easy to read but also as 
scientifically accurate as possible. We encourage authors 
to review the “Statistical Analyses and Methods in the 
Published Literature or The SAMPL Guidelines” while 
preparing their manuscript. 
 
Whenever possible, state absolute rather than relative risks. 
Submitting a BMJ Research 
article  
All BMJ Research articles should be 
submitted through our submission 
system at submit.bmj.com 
Completed ICMJE forms are 




Research article checklist  
We have produced a checklist 
on bmj.com to help you decide 
whether The BMJ is the right journal 
for your work. 
Another resource, the Authors’ 
Submission Toolkit: A practical 
guide to getting your research 
published, summarises general 
tips and best practices to increase 
awareness of journals’ editorial 
requirements, how to choose 
the right journal, submission 
processes, publication ethics, 
peer review, and effective 
communication with editors.  
If your work does not seem to 
fit in The BMJ you may prefer to 
try another journal with a more 
specialist or local readership, or a 
higher acceptance rate.  
reading only the abstract. 
 
Abstracts should be 250— 300 words long: you may need 
up to 400 words, however, for a CONSORT or PRISMA 
style abstract. MEDLINE can now handle up to 600 words. 
Abstracts should include the following headings, but they 
may be modified for abstracts of clinical trials or systematic 
reviews and meta—analyses according to the requirements 
on the the CONSORT extension for abstracts and the 
PRISMAextension for abstracts, respectively. 
 
•Objectives — aclear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
• Design — including factors such as prospective, 
randomisation, blinding, placebo control, case control, 
crossover,   criterion   standards   for   diagnostic   tests,    etc. 
• Setting — include the level of care, eg primary, 
secondary; number of participating centres. Be general 
rather  than  give the  name  of  the  specific  centre,   but 
give    the    geographical    location    if    this    is     important 
• Participants (instead of patients or subjects) — 
numbers entering and completing the study,  sex,  and 
ethnic    group    if    appropriate.    Give     clear     definitions 
of      how      selected,      entry      and      exclusion       criteria. 
• Interventions — what, how, when and for how long. This 
heading can be deleted if there were no interventions but 
should normally be included for randomised controlled 
trials,    crossover    trials,    and    before    and    after studies. 
• Main outcome measures — those planned in the 
protocol, those finally measured (if different, explain   why). 
• Results —  main  results  with  (for  quantitative  
studies) 95%  confidence  intervals  and,  where  
appropriate,  the   exact   level   of   statistical   significance 
and  the  number  need  to   treat/harm.   Whenever  
possible,     state     absolute     rather     than     relative   risks. 
• Conclusions — primary conclusions and their 
implications,    suggesting     areas     for     further     research 
if    appropriate.    Do    not    go    beyond     the     data     in 
the     article.     Conclusions     are      important      because 
this    is    often    the    only    part    that    readers    look     at. 
• Trial registration — registry and number (for clinical 
trials and, if available, for observational studies and 
systematic reviews). 
 
When   writing   your   abstract,   use   the   active   voice   but 
 
Please include in the results section of your structured 
abstract (and in the article’s results section) the following 
terms, as appropriate: 
 
For aclinical trial: 
• Absolute event rates among experimental and control 
groups. 
• RRR (relative risk reduction). 
• NNT or NNH (number needed to treat or harm) and its 
95% confidence interval (or, if the trial is of a public health 
intervention, number helped per 1000 or 100,000). 
 
For acohort study: 
• Absolute event rates over time (eg 10 years) among 
exposed and non—exposed groups 
• RRR (relative risk reduction) 
 
For a case control study: 
• OR (odds ratio) for strength of association between 
exposure and outcome 
 
For a study of a diagnostic test: 
• Sensitivity and specificity 
• PPV and NPV (positive and negative predictive values) 
 
The box stating what is known and what this study adds 
(see below) should also reflect accurately the above 
information. Under what this study adds, please  give  the 
one most useful summary statistic eg NNT. 
 
Please do not use the term ‘negative’ to describe studies that 
have not found statistically significant differences, perhaps 
because they were too small. There will always be some 
uncertainty, and we hope you will be as explicit as possible 
in reporting what you have found in your study. Using 
wording such as “our results are compatible with a decrease 
of this much or an increase of this much” or ‘this  study 
found no effect’ is more accurate and helpful to  readers 
than “there was no effect/no difference.” Please use such 
wording throughout the article, including the structured 
abstract and the box stating what the paper adds. 
 
Provide one or more references for the statistical package(s) 
used  to  analyse  the  data  —  for  example,  RevMan  for   a 
BMJ GUIDANCE FOR AUTHORS —   RESEARCH  




systematic review. There is no need to provide a formal 
reference for avery widely used package that will be familiar 
to general readers — for example, Stata — but please say in 
the text which version you used. 
 
   Reporting checklists and guidelines 
 
we would like to know if results have been posted, and 
where (please provide URLs or trial  registration  details). 
We require protocols for clinical trials that have now been 
published. We are pleased to consider articles based on 
longer systematic reviews and meta—analyses published at 
the Cochrane Library or HTA database. 
Download recommended 
reporting guidelines directly  
All reporting guidelines 
recommended here are available 
for full download from our 
Instructions for Authors page. 
Reporting guidelines promote clear reporting of methods 
and results to allow critical appraisal  of  the  manuscript. 
We ask that all manuscripts be written in accordance with 
the appropriate reporting guideline. Please submit as 
supplemental material the appropriate reporting guideline 
checklist showing on which page of your manuscript each 
checklist item appears. A complete list of guidelines can be 
found in the website of the Equator Network. Below is the 
list of most often used checklists but others may apply. 
 
• In most cases, we will follow suggestions  for  preferred 
and non—preferred reviewers. If you have suggestions for 
preferred reviewers, please provide us with their  names 
and contact details; we may invite some of them to review 
the paper. Please also let us know if you would not like us to 
invite specific reviewers to look at your work but provide an 
explanation for your request. 
 
• Assurance that a study funded or sponsored by industry 
follows  the  guidelines  on  good   publication   practice. 
These GPP2 guidelines aim to  ensure  that  such  studies  
are published in a responsible and ethical manner. The 
guidelines cover  companies’  responsibility  to  endeavour 
to publish results of all studies, companies’ relations with 
investigators, measures to prevent redundant or premature 
publication, the roles of authors and contributors, and the 
role of professional medical writers. 
 
• Assurance that any article written by a professional 
medical writer follows the guidelines by the European 
Medical Writers’ Association on the role of professional 
medical writers. The guidelines emphasise the importance 
of respecting  widely  recognised  authorship  criteria,  and  
in particular of ensuring that all people listed as named 
authors have full control of the  content  of  articles.  The  
role of professional medical writers must be transparent. 
Please name any professional medical  writer  among  the 
list of contributors to any article for The BMJ (not only 
original research articles), and specify in the formal funding 
statement for the article who paid the writer. Writers and 
authors must have access to relevant data while writing 
articles. Medical writers  have  professional  responsibilities 
to ensure that the articles they write are scientifically valid 
and are written in accordance with generally accepted 
ethical standards. 
 
Additional information that must be included with reports 




A cover letter is your opportunity to introduce your study 
   to the editor,  highlighting  the most important findings  and 
Trial Registration 
In accordance with the International Committee of Medical 
Journal Editors’ Recommendations for the Conduct, 
Reporting,  Editing,  and  Publication  of  Scholarly   Work 
Find out more about reporting 
trialregistration  
All recommended trial registration 
reporting guidance is available 
to view on our Instructions for 
Authors page. 
novelty. Please include the following information: 
 
• Details  of  previous  publications  from  the  same    study 
— including in scientific abstracts  or  partial  reports  by  
the media at scientific meetings and in foreign language 
journals. 
 
• Details of any previous  publication  of  the  same  study  
in electronic form, including on any preprint server.  The 
BMJ does not  consider  posting  of  protocols  and  results  
in   clinical   trials   registries   to   be   prior   publication, but 
in  Medical  Journals,  The BMJ  will  not  consider  reports of 
clinical trials unless they were registered prospectively 
before recruitment of any participants. For trials that 
started before 1 July 2005 retrospective registration will be 
acceptable, but only if completed before submission of the 
manuscript to the journal. The trial registration number 
and name of register should be included at the end of the 
structured abstract. The BMJ accepts registration in any 
registry that is a primary register of the WHO International 
Clinical Trials Registry Platform (ICTRP) or in ClinicalTrials. 
gov, which is a data provider to the WHO ICTRP. 
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RECOMMENDED REPORTING  GUIDELINES  
Clinical trials: For a clinical trials, use the CONSORT 
checklist and also include a structured  abstract  that  
follows  the  CONSORT  extension  for  abstract   checklist, 
the CONSORT flowchart and, where applicable, the 
appropriate CONSORT extension statements (for example, 
for cluster RCTs, pragmatic trials,  etc.).  A  completed  
TIDieR checklist is also helpful  as  this  helps  to  ensure  
that trial interventions are fully  described  in  ways  that  
are reproducible, usable by other clinicians, and clear 
enough   for   systematic  reviewers  and  guideline   writers. 
Systematic reviews and meta—analysis: For systematic 
reviews or  meta—analysis  of  randomised  trials  and  
other evaluation studies, use the PRISMA checklist and 
flowchart and use the PRISMA structured abstract checklist 
when writing the structured abstract. 
 
Diagnostic accuracy: STARD checklist and flowchart 
Observational studies: For observational studies, use the 
STROBE checklist and any appropriate extension STROBE 
extensions. 
Genetic risk prediction: GRIPS guidelines. 
Economic evaluation studies: CHEERS guidelines. 
Prediction models: For studies developing, validating or 
updating a prediction model, use   TRIPOD. 
 
For articles that include explicit statements of the quality 
of evidence and strength of recommendations, we prefer 
reporting using the GRADE system. 
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STATEMENTS THAT MUST BE INCLUDED IN RESEARCH SUBMISSIONS 
Public and Patient Involvement statement: 
The BMJ is encouraging active patient and public involvement in clinical research as part of its patient partnership strategy. 
This is research which is “co produced” with patients, carers, or members of the public. To support coproduction of research 
we request that authors provide a Patient and Public Involvement statement in the methods section of their papers. We 
request this to both encourage the movement and ensure that BMJ readers can easily see whether, and if so how, patients 
and the public were involved in the research. If they were not involved in any way this information should be formally 
documented in the Patient and Public Involvement statement. As co production of research with patients and the public is 
relatively new we appreciate that not all authors will have involved them in their studies. We also appreciate that patient/ 
public involvement may not be feasible or appropriate for all papers. We therefore continue to consider papers where they 
were not involved. 
 
The Patient and Public Involvement statement should provide a brief response to the following questions, tailored as 
appropriate for the study design reported: 
• At what stage in the research process were patients/public first involved in the research and how? 
• How were the research question(s) and outcome measures developed and informed by their priorities, experience, and 
preferences? 
• How were patients/public involved in the design of this study? 
• How were they involved in the recruitment to and conduct of the study? 
• Were they asked to assess the burden of the intervention and time required to participate in the research? 
 
In addition to considering the points above we advise authors to look at guidance for best reporting of patient and public 
involvement as set out in the GRIPP2 reporting checklist. Even if patients were not involved in the study described, we 
suggest that you consider enlisting their help in disseminating the research findings. 
 
If information detailing whether there was patient and public involvement, or not, is missing in the submitted manuscript we 
will request authors to provide it. Where they have been involved we consider it good practice for authors to name and thank 
them in the contributorship statement after seeking their permission to do so; and to clearly identify them as patient/public 
contributors. When they have contributed substantially and meet authorship criteria they should be invited to coauthor 
the manuscript. Please note also note that it’s The BMJ policy to send relevant research papers for review by patient 
reviewers alongside academic peer  reviewers. 
 
Ethics approval: 
All research studies published in The BMJ should be morally acceptable, and must follow the World Medical Association’s 
Declaration of Helsinki. To ensure this, we aim to appraise the ethical aspects of any submitted work that involves human 
participants, whatever descriptive label is given to that work including research, audit, and sometimes debate. This policy 
also applies on the very rare occasions that we publish work done with animal participants. The manuscript must include 
a statement that the study obtained ethics approval (or a statement that it was not required), including the name of the 
ethics committee(s) or institutional review board(s), the number/ID of the approval(s), and a statement that participants 
gave informed consent before taking part. 
 
Transparency statement: 
Please include in your manuscript a transparency declaration: a statement that the lead author (the manuscript’s guarantor) 
affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important 
aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, 
registered) have been explained. The BMJ is committed to making the editorial process transparent and ethical. The BMJ’s 
transparency policies are accessible from this link. 
 
Role of the funding source: 
Please include in the funding statement a statement giving the details of all sources of funding for the study. As appropriate, 
the statement must include a description of the role of the study sponsor(s) or funder(s), if any, in the study design; in the 
collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for 
publication. In addition, the statement must confirm the independence of researchers from funders and that all authors, 
external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take 
responsibility for the integrity of the data and the accuracy of the data analysis is also required. 
 
If you are submitting an original article reporting an industry sponsored clinical trial, postmarketing study, or other 
observational study please follow the guidelines on good publication practice (GPP2) and on properly reporting the role 
of professional medical writers. Another resource, the “Authors’ Submission Toolkit: A practical guide to getting your 
research published” summarises general tips and best practices to increase awareness of journals’ editorial requirements, 
how to choose the right journal, submission processes, publication ethics, peer review, and effective communication with 
editors — much of which has traditionally been seen as mysterious to authors. 
 
The BMJ will not consider for publication any study that is partly or wholly funded by the tobacco industry, as explained in this 
editorial. 
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Data sharingwith Dryad  
The BMJ has partnered with the 
Dryad digital repository datadryad. 
org to make open deposition easy 
and to allow direct linkage by doi 
from the dataset to The BMJ's article 
and back (for The BMJ's articles' 











Find out more about our Open 
Access options  
For additional information, please 
see the section of instructions 
to authors on copyright, open 
access, and permission to reuse 
your article. For further information, 
contact  openaccess.bmj@bmj.com. 
Data sharing 
We require a data sharing statement for all research 
papers. For papers that do not report a trial, we do not 
require that authors agree to share the data, just that they 
will say whether they will. 
 
For reports of clinical trials, we ask  that  the  authors 
commit to making the relevant anonymised patient level 
data available on reasonable request (see editorial). This 
policy applies to any research article that reports the main 
endpoints of a randomised controlled trial of one or more 
drugs or medical devices in current use, whether or not the 
trial was funded by industry. 
 
"Relevant data" encompasses all anonymised data on 
individual patients on which the analysis, results, and 
conclusions reported in the paper are based. As for 
"reasonable request," The BMJ is not in a position to 
adjudicate, but we will expect requesters to submit a 
protocol for their re-analysis to the authors and to commit 
to  making  their  results  public.  We   will  encourage   those 
requesting data to send a rapid response to thebmj.com, 
describing what they are looking for. If the request is refused 
we will ask the authors of the paper to explain why. 
 
In addition, we will follow the new ICMJE data sharing 
policy that goes into place on July 1, 2018 (see editorial): 
manuscripts  submitted  to  ICMJE  journals  that   report   
the results of clinical trials must contain a data sharing 
statement that indicates whether individual de-identified 
participant data (including data dictionaries)  will  be 
shared; what data in particular will be shared; whether 
additional, related documents will be available (study 
protocol, statistical analysis plan, etc); when the data will 
become available and for how long; by what access criteria 
data will be shared (including with whom, for what types of 
analyses, and by what mechanism). Clinical trials that begin 
enrolling participants on or after January 1, 2019 must also 
include a data sharing plan in the trial’s registration. If the 
data sharing plan changes after registration this should be 
reflected in the statement submitted and published with the 
manuscript, and updated in the registry record. 
 
We encourage authors  of all research  articles  in The BMJ  
to link their articles to the raw data from their studies. For 
clinical trials, we require data sharing on request as a 
minimum and- if authors of such trials are willing to go 
further and share the data openly, so much the better. 
 
SUPPLEMENTAL MATERIAL, VIDEO  
• Original raw data: If you think they will help our reviewers 
(and maybe readers), or if we specifically request them. 
Please note our policy on data sharing, explained  above. 
• Video , image , table, and audio files: If these add 
educational value to your article. We may be able to publish 
additional files on  bmj.com. 
• Video abstract: These can summarise your findings and 
will be posted on bmj.com alongside your paper. You can 
find additional information about video abstracts in this 
editorial,  and here. 
• Public and patient involvement materials used in your 
research 
• Copies of any non—standard questionnaires and 
assessment schedules used in your research 
• Copies of patient information sheets used to obtain 
informed consent for the study, or to comprise or deliver 
the intervention in a clinical trial 
• Copies of closely related articles you’ve published 
(particularly important when details of the study are 
published elsewhere) 
• Copies of any previous reviewers’ reports on this article 
SUMMARY BOXES 
Please produce a box offering a thumbnail sketch of what your article adds to the literature. The box should be divided into 
two short sections, each with 1—3 short sentences. 
 
Section 1: What is already known on this topic 
In two or three single sentence bullet points, please summarise the state of scientific knowledge on this topic before you did 
your study, and why this study needed to be done. Be clear and specific, not vague. 
 
Section 2: What this study adds 
In one or two single sentence bullet points, give a simple answer to the question “What do we now know as a result of this 
study that we did not know before?” Be brief, succinct, specific, and accurate. For example: “Our study suggests that tea 
drinking has no overall benefit in depression.” You might use the last sentence to summarise any implications for practice, 
research, policy, or public health. DO NOT make statements that are not directly supported by your data. 
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OPEN ACCESS FOR RESEARCH  
All research papers in The BMJ are published with Open 
Access. Open access articles may be reused according to 
the relevant Creative Commons licence. The BMJ’s default 
licence for open access publication of research is the 
Creative Commons Attribution Non Commercial licence 
(CC BY—NC 4.0). But where the funder requires it the 
author can select the Creative Commons Attribution (CC 
BY 4.0) licence during the submission process (funders 
who mandate CC BY include the Wellcome Trust, RCUK, and 
MRC). 
 
To support this, we ask authors to pay an open access 
article publishing charge/fee of £3000/$4800 (excluding 
VAT) on acceptance of their paper. We can offer discounts 
and waivers for authors who cannot pay. Consideration 
of the paper is not related to whether authors can or 
cannot pay the fee. We will ask for the fee only once we 
have accepted a paper, and we will send an invoice only 
once authors tell us. Please do not contact editors about 
open access fees: neither editors nor reviewers will know 
whether a fee is payable, and administrative staff will 
handle payments and all associated correspondence. 
 
A number of institutions have open access institutional 
memberships with BMJ (the publishing group), which 
either cover the whole cost of open access publishing for 
authors at participating institutions or allow authors to 
receive a discount on the article processing charge. 




4.2 RESEARCH METHODS AND REPORTING 
 
The BMJ is also interested in original studies on research 
methodology, research reporting, peer review, and 
evidence based medicine. The same criteria apply to 
these as to all the other types of research we consider. 
We will give priority to studies that will be relevant and 
interesting to enough of our readers (not only to editors, 
statisticians, and other experts on methodology) and 
will help them make better decisions when conducting 
research; searching for evidence; or using research 
evidence in their practice, their teaching, or their 
learning. We also publish essays about designing, 
conducting, and reporting research, in our research 
methods and reporting  section. 
 
We are willing to consider papers that present new or 
updated research reporting guidelines, but only if the 
guideline pertains to a study type that we publish in   
The BMJ. The checklist itself must be included as part   
of the paper. We prefer to be the only journal publishing 
the guideline, but under some circumstances we will 
consider copublication with up to two other journals. 
 
For an example of how to format a reporting guideline to 
appear in our research methods and reporting section, 
see here. 
 
Research Methods and Reporting articles should have the 
elements below. 
 
Word count and style 
We do not set fixed word count limits for RMR articles. None- 
theless, we ask you to make your article concise and make 
every word count. For some submissions this might be pub- 
lished in full on bmj.com with a shorter version or abstract 
in the print BMJ. 
 
Title and abstract 
A short title is followed by an 100—150 word italicised sum- 




Articles should begin with a brief paragraph that captures 
readers’ attention and explains the aim of the piece. 
 
Text 
The body of the text should be broken up under subheadings 
that provide a logical narrative structure. Avoid acronyms 
and abbreviations  unless  they  are  universally recognised 
e.g. DNA. The evidence on which key statements are based 
should be explicit and referenced, and the strength of the 
evidence (published trials, systematic reviews, observational 
studies, expert opinion etc.)  addressed. 
 
Boxes, tables and figures 
Include tables, boxes, or illustrations (clinical photographs, 
imaging, line drawings, and figures) to enhance the text and 
add to or substantiate key points made in the body of the 
article. Figures may be in color. Worked out examples that 
 
use specific methods under discussion can be included as 
additional boxes. If appropriate, include a box of linked infor- 
mation such as website urls for those who want to pursue the 
subject in more depth. 
 
Web extras 
We may be able to publish on bmj.com some additional 
boxes, figures, and references. Please included these as a web 
reference list in the main article file. You may also include 
suggestions for linked podcasts or video clips, as appropriate. 
 
Contributors and sources 
We ask for a 100—150 word supplementary paragraph 
(excluded from word count) to explain the article’s prove- 
nance. It should include the relevant experience and exper- 
tise of each author, his or her contribution to the paper, and 
the sources of information used to prepare it. One author 
must be nominated as the guarantor of the article. Include a 
statement of sources and selection criteria. 
Key messages box 
Include up to four sentences, in the form of short bullet 
points, highlighting the article’s main points. 
 
References 
Must be in Vancouver style and should be kept to a mini- 
mum; ideally no more than 20. 
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RESEARCH METHODS AND REPORTING — OPEN ACCESS  
Research Methods and Reporting articles are not 
published as Open Access by default. 
 
If you would like your article to be published with an Open 
Access licence, we recommend requesting this directly on 
submission. Standard BMJ Open Access fees apply to all 
Research Methods and Reporting articles published with 
an Open Access licence. Find out more about our Open 
Access policy here. 





Presubmission enquiries for a 
BMJ Analysis article  
If you are unsure if your work is 
suitable for The BMJ’s Analysis 
section we are willing to consider 
succinct pre—submission inquiries, 
please complete this form and 





























Analysis prepublication  history 
In most cases we will publish the 
prepublication history alongside 
an accepted analysis article. This 
prepublication history comprises all 
previous versions of the manuscript, 
the report from the manuscript 
committee meeting, the reviewers’ 
comments, and the authors’ 
responses to all the comments 
from reviewers and editors. In 
rare instances we may determine 
after careful consideration that we 
should not make certain portions of 
the prepublication record publicly 
available. 
4.3 ANALYSIS 
The Analysis section of the journal is a forum for 
scholarly debate articles which discuss topical clinical, 
scientific, ethical, and policy issues that matter to doc- 
tors and patients. We look for our analysis articles to be 
interesting and thought—provoking to a broad range 
of readers based all over the world, including policy 
makers, doctors of all specialties, and other healthcare 
professionals. They should present a clearly reasoned 
argument, backed by an even—handed look at the 
evidence, with a clear key message. Articles that set 
out hypotheses are not suitable unless they contain a 
convincing attempt to test them. 
 
Analysis articles should have the following   elements: 
 
Word count and style 
The BMJ has an international readership that includes policy 
makers, health professionals, and doctors of all disciplines. 
Authors are advised to keep this readership in mind and to 
write their article for the non—expert. It’s important to avoid 
jargon. Specialised terminology and references to organisa- 
tions or practices that are specific to one country need to be 
explained. Clear writing and an attractive presentation are 
essential. Analysis papers should be 1800—2000 words 
long. 
 
Title, standfirst and introduction 
A short title is followed by an italicised single sentence (the 
standfirst) which encapsulates the article’s central message. 
Articles should begin with a brief paragraph that captures 
readers’ attention and explains the aim of the  piece. 
 
Text 
The body of the text should be broken up under sub— 
headings that provide a logical narrative structure. Avoid 
acronyms and abbreviations unless they are universally rec- 
ognised eg. DNA. The evidence on which key statements are 
based should be explicit and referenced, and the strength  
of the evidence (published trials, systematic reviews, obser- 
vational studies, expert opinion, etc.) made clear. Articles 
should present a balanced, even—handed look at the evi- 
dence rather than selectively citing evidence that supports 
a particular view. 
 
Boxes, tables and figures 
These should extend and substantiate points made in the 
body of the paper. Any additional material should be con- 
cise. 
 
Key messages box 
This should be at the end of the article and include 2 to 4 
points summing up the main conclusions. When submit- 
ting your article at submit.bmj.com, please enter your key 
messages when prompted to enter the abstract. 
 
References 
Must be in Vancouver style and should be kept to a mini- 
mum; ideally no more than  20. 
Contributors and sources 
We ask for a 100—150 word supplementary paragraph 
(excluded from word count) to explain the article’s prov- 
enance. It should include the relevant experience and 
expertise of each author, his or her contribution to the 
paper, and the sources of information used to prepare it. 
One author must be nominated as the guarantor of the 
article.You are welcome to invite co—authors to work with 
you on the article. We suggest including 2—3 co—authors 
with different locations and perspectives to help ensure 
articles are international in scope and accessible to our 
broad readership online and in print. 
 
Report of patient involvement 
As The BMJ is seeking to advance partnership with 
patients, we also ask authors to seek their input into arti- 
cles wherever relevant, and document their involvement 
as patient contributors or coauthors. 
 
Conflicts of Interest 
All authors should read our competing interests policy 
and include the appropriate declaration in their manu- 
script. Where a competing interest exists that might dis- 
qualify an author from contributing, it is wise to discuss 
it with a BMJ editor before writing the article. 
 
Licence 
We require the manuscript to include the following state- 
ment: 
“The Corresponding Author has the right to grant on behalf 
of all authors and does grant on behalf of all authors, an 
exclusive licence (or non exclusive for government employ- 
ees) on a worldwide basis to the BMJ Publishing Group 
Ltd (“BMJ”), and its Licencees to permit this article (if 
accepted) to be published in The BMJ’s editions and any 
other BMJ products and to exploit all subsidiary rights, as 
set out in our licence.” 
 
Peer review 
The BMJ has fully open peer review for analysis articles. 
This means that every accepted analysis article submit- 
ted will have its prepublication history posted alongside 
it on thebmj.com. This prepublication history comprises 
all previous versions of the manuscript, the report from 
the manuscript committee meeting, the reviewers’ signed 
comments, and the authors’ responses to all the comments 
from reviewers and editors. Authors are welcome to suggest 
names of suitable reviewers, including patient reviewers. 
 
Post—submission 
• All submissions are read in full by one or more members 
of the editorial team. 
• Articles that pass the initial editorial screen are sent for 
external peer review. 
• Articles are then discussed at a regular analysis committee 
meeting where editors make one of three decisions: reject; 
reject with offer to resubmit; or provisionally accept. 
 
Accepted analysis articles are published online at bmj.com, 
the canonical version of The BMJ. A proportion of accepted 
analysis articles will also be published in the print journal. 
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The BMJ publishes different types of educational 
articles to engage and challenge a range of postgraduate 
doctors and clinical researchers internationally. We 
strive to publish articles that are original in their content 
and/or presentation, and cannot be found elsewhere 
or in textbooks. We prioritise topics and situations 
that are common or have serious consequences, have 
international appeal, and that interest a variety of 
doctors, including GPs and specialists. 
 
We encourage authors to write in teams, including those 
from other specialties, professions, and countries. We 
   ask that one author is routed in the clinical environment 
What do we mean bypatient 
involvement and co—production 
in Education?  
We believe that patient involvement 
strengthens content. Read our 
full guidance on what we mean 
by patient involvement and co— 
production.  
Patient consent forms 







Presubmission enquiries for BMJ 
Education articles  
Education article proposal forms 





of the  intended  reader.  We encourage  authors  to 
write in plain English, to be clear about where there is 
uncertainty, and to include numbers and phrases where 
possible that will help doctors in conversation with their 
patients. 
 
Our educational articles are shaped by two initiatives: 
• We believe that financial interests can distort education 
articles and we minimise or exclude authors who we judge 
have such a conflict. 
• We encourage authors to seek input from patients either 
to inform the scope, develop the content, contribute to, or 
co—author articles. 
 
Submission process and presubmission enquiries 
We receive more articles and suggestions than we can 
publish. We require all authors to submit proposals using 
the forms to the left, which pose the following questions: 
 
• What is your idea? 
• Can you sum up the aim of your article in a sentence? 
BMJ declaration of competin 










BMJ policies  
Find out more about The BMJ’s 
editorial and ethical policies 
• Why is the topic important to The BMJ’s readers? 
• What is the prevalence of the symptom/condition/situa- 
tion you wish to write about? 
• Why cover it now? Has something new happened? 
• What has The BMJ’s Education section covered on this 
topic in the last five years? What will your contribution 
add? 
• Can you provide the key evidence/references you might 
use? 
• Why are your writing team well placed to cover the 
topic? 
• Have you thought about what a patient would say 





Preparing your manuscript 
We want our readers to have the ability to share decisions 
with their patients and make clear for them the degree of 
certainty ( or lack of it) about a potential course of action. 
We therefore ask that you follow these recommendations: 
 
• Consider including in your manuscript a box explaining 
your strategy to search for evidence. It should include a 
search date, the sources searched, and brief inclusion 
criteria. 
• Clearly distinguish suggestions made based on your 
experience, standard practice, guidelines, and evidence. 
• Provide specifics about the evidence you discuss. For 
example, for key statements, please say: “A large, well 
conducted, randomised controlled trial showed INSERT 
number [CI] and or p value”. “The findings of a small 
case series suggest...”. “A subgroup analysis found…”. 
etc. 
• Use absolute numbers or explain why you have not 
used them. 
• Consider how these numbers can be communicated by 
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Competing interests 
The BMJ will not consider authors with financial interests 
when writing Education articles. It is important that we 
understand the financial interests of every author, and can 
judge to what extent we believe that they may be relevant to 
the article that you propose. We do not publish content from 
authors who we judge have relevant financial ties to the 
industry (excluding State of the Art reviews, Therapeutics 
articles, and Summaries of NICE Guidelines). The relevance 
of declared interests are judged by the BMJ team. This 
applies to every author. Any additional authors and their 
financial interests must be discussed and agreed with the 
commissioning editor before the article issubmitted. 
Patient involvement 
As part of our drive to co—produce our content with patients 
we ask that you seek patient input into articles at the 
planning stage. 
 
We ask all authors to what extent patients have been 
involved in and how involvement has changed an article. 
We ask that all writing encourages honesty and partnership 
with patients. Where uncertainty exists, share it. Where data 
exists present the numbers in a way that can be shared with 
the patient (absolute numbers, natural frequencies, and 
graphics). Use language that empowers patients to make the 
right choices for them in their situation (write that a doctor 
should/could offer a test, rather than should do a test). 
 
When patients are involved in the manuscript, we ask for 
their consent. We have two types of consent forms for BMJ 
education articles: 
 
• A patient consent form is required if any anonymised 
patient information is included in the review. Consent is 
needed for images even if the patients are not identifiable 
for example, in X—rays and histology slides, and for patients’ 
stories/vignettes even if details are anonymised. 
 
• A patient contributor form is required for any patients 
who are named within the review, for example, patient co— 
authors, patient contributors or named authors of patient 
stories. 
POLICIES FOR EDUCATION ARTICLES  
Authorship 
Education articles can have can have up to four authors. 
One author should be from the relevant specialty  or 
setting, unless agreed otherwise. For example, if the article 
discusses presentation to the emergency department one 
author should be an emergency care doctor. All authors 
should meet authorship criteria. We welcome authors or 
contributions from allied health professions and patient 
authors, and actively encourage authors from a primary care 
background. 
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the clinician read to 
their patient in a clear 
way. 
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Education article types          
Article Type Focus/Audience  Content  Word Limit 
Clinical Updates These articles provide an up to date overview of a clinical condition. The content should be evidence based, aimed at non—specialists and have international 
appeal. It should include a broad update of recent developments (from the past 1—2 years) and their likely clinical applications in primary/community and 
secondary/hospital care. 
1800 words, 
maximum of 40 
references 
Practice Pointer These are practical, often problem based articles. They should help 
clinicians who are not specialists in a particular field know “how to” to 
approach a problem, diagnosis or management better. 
 
Easily Missed This series highlights conditions that are often missed at first presentation 
in general practice or the emergency department. For the condition in 
question provide evidence that the condition may be misdiagnosed or 
that diagnosis may be delayed and that timely recognition will benefit the 
patient. The condition should be reasonably common (likely to present 
at least once a year to a full—time primary care practitioner) or is serious 
and delayed diagnosis is likely to worsen prognosis. The condition should 






Rational Testing  These articles update clinicians on the best initial use of imaging methods 
or diagnostic tests for common or important problems. The aim of these 
articles is to equip frontline clinicians to exclude and diagnose important 
conditions, and to know when to refer to a specialist. Imaging articles will 
require relevant high—resolution images. 
There is no strict format to this article type. Consider the use of questions to 
draw the reader through such as: what are the risk factors? How do patients 
present? How is it diagnosed? When should we refer patients? How is it 
managed? 
Include the following subheadings: 
Case history: Brief fictitious case illustrating how a patient might present and 
be diagnosed. 
Introduction: Description of the condition. Outline recent data on incidence, 
preferably from primary and/or emergency care. 
Why is it missed? Provide recent evidence of delayed diagnosis or 
misdiagnosis, which may include audit or medicolegal data if no other 
evidence is available. Describe factors which contribute to missing this 
diagnosis. 
Why does this matter? Describe the consequences of missed diagnosis. 
How is it diagnosed? Subdivide this into “Clinical features” and 
“Investigations” that are readily available. Comment on presence, absence 
and quality of predictive values or sensitivities/specificities (or frequencies for 
key clinical findings) of the clinical features and investigations mentioned. 
How is it managed? This should be discussed in 3—4 sentences, as it is not 
the focus of the series. 
Include the following subheadings: 
The patient: Describe the presentation of a common or important condition 
whose management will be influenced by ordering the right test. 
What is the next investigation? List the most important initial tests. Discuss 
the rationale, limitations and benefits of each, based on the evidence. Include 
sensitivities/specificities or positive/negative predictive  values. 
Please avoid long lists of differential diagnoses and tests, as these are generally 
not helpful. 
1,000 words and 
15 references 
 













These articles describe how clinicians might use a (one) consultation to 
tackle a common scenario, in primary or secondary care. Articles must 
address a tightly framed issue for example how to explore a new symptom 
(eg tingling fingers), explain a diagnosis of a condition (eg Parkinson’s 
disease, or an aspect of its management) or act in an urgent situation, such 
as on receipt of a high INR reading. 
Include the following subheadings: 
What to cover. 
What to do. 
700 words and 
10 references 
Uncertainties This series highlights areas of practice that lack convincing evidence. Include the following subheadings: 
Introduction: Succinctly describe the uncertainty phrased as a question. 
What is the evidence of uncertainty? Discuss the type and quality of the 
evidence confirming uncertainty or showing variation in clinical practice. If a 
relevant systematic review does not exist on this topic, please mention this. 
Is ongoing research likely to provide relevant evidence? Identify the key 
research questions that would address the evidence gap (and formulate them 
in PICO format — population, intervention, comparison, and outcome). Indicate 
if studies are underway that may address the gap. 
What should we do in the light of the uncertainty? Provide practical 
guidance to clinicians on what to do. 
Include a box of your search strategy for the body text and a second box of 
the registries you searched to identify forthcoming studies to address the 
uncertainty 
1,000 words and 
15 references 
Essentials These articles provide a basic comprehensive summary of a topic that 
the reader should already know something about. They are aimed at 
non specialists. Essentials articles are not meant to give readers a full 
update, and may not be telling readers anything new. Ideally, we prefer an 
international author team and focus. 
Therapeutics The BMJ's Therapeutics series covers new drugs in clinical use or old drugs 
with important new indications or controversy. Articles are about 1000 
words long, and aimed at doctors who aren't specialists in the therapeutic 
field. They focus on what frontline clinicians need to know before 
prescribing the drugs, or treating patients already taking them. The editorial 
that launched the series is here: http://www.bmj.com/content/342/bmj. 
d37 
The articles follow a broad structure that outlines the evidence and best 
practice followed by some practical guidance on ‘How to do it’ perhaps with 
the use of short fictitious tasters. Authors should present the challenges and 
include links to other resources. 
 
Detailed structures for this article type will be discussed during the 
commissioning process between author/editor. 
1,000 words and 
15 references. 
 
1,000 words and 
15 references 
Change Page This series highlights where practice may need to change. Include the following subheadings: 
The clinical problem: outline the current diagnostic/treatment approach and 
its limitations, giving evidence of current practice. End with your actual proposal 
for change. 
The evidence for change: include a box of methods (i.e. how you selected 
the evidence underpinning your proposal.) Indicate the type and quality of the 
evidence when citing each study. Consider adding a Box describing the pivotal 
studies. 
Barriers to change: Describe them (e.g. pragmatic difficulties, risks, 
contraindications.) 
How should we change our practice: give a practical description of what 
changes should be made, based on the evidence. 
1,000 words and 
15 references 
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Article Type Focus/Audience Content Word Limit 
What Your Patient 
Is Thinking (WYPIT) 
This is a series led, and edited and written by patients and their carers and 
contain messages that are thought provoking, and challenging for readers 
of The BMJ, along the lines of “What I wish you [The BMJ’s audience] knew, 
and why.” 
 
Who can write one? 
Anyone who is using the healthcare system, either on their own behalf or for 
someone else. To avoid getting overwhelmed by ‘doctor as patient’ stories, 
we prioritise pieces from those who are not health professionals. Authors 
should bear in mind that our readership is international and avoid detailed 
comments about specific national policies. Some people find it difficult to 
turn a personal story into something doctors can learn from but if the story 
is still powerful we are happy to consider publication of articles in another 
form, for example as a BMJ blogs/opinion piece. If you have an idea for a 
WYPIT article and want to discuss it before submission please get in touch 
with BMJ patient editor Sally Carter (scarter 
@bmj.com) and include an outline of what you would like to say. 
 
What these articles are not 
Complaints about or praise of a named healthcare professional or clinic/ 
hospital; 
Legal cases which are not resolved; 
A personal anecdote or journey through the healthcare system with no 
learning points; 
Written on behalf of someone else (for example, a carer must write about 
being a carer, not what they suspect it is like to be the patient) 
Promotion of a particular treatment or style that other healthcare 
professionals cannot 
Summary Box: “What you need to know” This should include three short 
bullet points encapsulating the practical things that health professionals might 
consider doing as a result of reading the article. The editor will work with you to 
edit the text and may ask doctors working in The BMJ what elements they think 
are the most powerful to help the article. 
Other boxes: We are happy to consider a second box containing, for example, 
useful websites or other learning resources for health professionals. We may 
also suggest you add some extra explanatory information in a short box if we 
think the context of your care needs a bit more elaboration. 
 
What may be added: 
Illustrations: Articles are usually published with an accompanying illustration. 
This is commissioned after the article has been accepted. 
Questions for Doctors: To encourage ongoing professional learning and 
development we host a series of reflective questions for doctors based on the 
content of many of our education article, including WYPITs. These are written by 
one of the editors and ask the reader what they might do differently having read 
your article. (The authors of the education articles are not routinely asked to be 
involved in this process). 
 
Content style 
In the education section of the journal where WYPITs are published we aim to 
provide up to date and original content to engage and challenge postgraduate 
doctors and clinical researchers internationally. We askauthors to write in plain 
English, rather than academic sounding language, and we avoid an over— 
prescriptive tone. For example, we encourage authors to use words such as 
‘suggest’, ‘might’, or ‘offer’ when describing how readers might change their 
practice (rather than use rigid statements such as ‘always’, ‘never’, ‘must’, 
‘should’). 
Other considerations 
We encourage all authors to sign their articles but are happy to discuss 
anonymity is this is prefered. We also need authors to sign a competing interest 




box at the end of 
each piece, called 
“What You Need 
To Know.” 
Summary of NICE 
Guidelines 
These article types are solely commissioned by our editors.   
State of the Art 
Reviews    
Minerva Pictures These are pictures which offer an educational message and which will publish clearly and depict the abnormality obviously. Pictures we are more likely to 
accept are those which offer an educational message and which will publish clearly and depict the abnormality obviously. Minerva pictures with the following 
characteristics are not usually accepted because they lack educational value for general readers: 
• Showing foreign bodies 
• Showing the results of gross trauma 
• With poor image quality, even if the story is sound and interesting 
• With pictures and stories which are simply “textbook” presentations 
• Reporting cases of very rare clinical presentations 
• Submissions which simply criticise other clinicians, or the patient. 
Please provide two or three sentences (no more than 100 words) explaining the picture, and please send us the signed consent to publication from the 
patient. Please make sure that the text includes all authors’ names together with their job titles and addresses (including departments’ and hospitals’ 
names) at the time the patient was seen, and the email address of the corresponding author. We also need to recieve statements of competing interests 
and copyright/licence. 
NB: Minerva pictures/articles are not indexed in PubMed. 
Less than 100 
words 
Endgames The BMJ does not publish standard case reports. We do, however, publish Writing up a Case Review: Varies — authors 
articles about real cases if they are suitable for presentation in specific Case Review articles must include a short vignette and 3 questions with short will be contacted 
educational formats. These include Endgames case reviews and picture answers for The BMJ’s print edition and three longer discussions/answers for by our editors 
quizzes. bmj.com . Please ensure all information required to answer the questions is prior after forms 
contained in the vignette. We encourage accompanying clinical illustrations. have been 
Endgames is designed to help doctors across all levels and specialties Please cover important points for generalists including red flags and advice considered 
test their knowledge and reflect on their practice for continuing medical for patients. 
education. Endgames articles are based on genuine clinical scenarios. The discussions/long answers must be evidence based with relevant 
We only consider common topics rather than clinical rarities (or very rare  citations. 
complications of common diseases, which may be more suitable for A maximum of four authors is allowed for each Case Review article, and each 
BMJ Case Reports journal.) We consider hospital and community based author should have no more than 2 articles under consideration at any one 
scenarios providing the content is generalisable. We do not publish articles time. 
if the patient management is controversial. 
Writing up a Spot Diagnosis: 
At least one author must be a specialist (consultant, post CCT, or equivalent)  Spot Diagnosis articles must based on a clinical image that is distinctive of 
in a field relevant to the topic and all authors must satisfy our strict a particular condition. A short vignette should accompany the image and 
competing interest criteria. The online competing interests form must be there should be one question relevant to the image and diagnosis. The article 
completed by all authors prior to submission. To avoid duplication of large should include no more than two learning points as a take home message for 
paragraphs of text from textbooks or journals, we ask authors to provide a readers. A maximum of two authors is allowed for each Spot Diagnosis article, 
signed originality of work attestation form. and each author should have no more than 2 articles under consideration at 
any one time. 
 
Which cases are suitable? 
Please check our archive as we do not repeat topics within 3 years. We only consider common topics rather than clinical rarities and are unlikely to accept 
an article if the prevalence of the condition is less than 1/100 000 in the population. This includes very rare complications of common diseases, which may 
be more suitable for BMJ’s Case Reports journal. We consider hospital and community based scenarios providing the content is generalisable. We do not 
publish articles if the patient management is controversial. If you wish to inquire about the suitability of a particular case for Endgames please complete 
this form. 
 




Pitching Minerva and Endgames 
All Minerva articles should be 
submitted directly through our 
online editorial office at submit. 
bmj.com. Written consent is 
required from every patient, 
regardless of whether the patient 
can be identified or not in the 
picture.  
All Endgame articles should be 
proposed via our online form, 
available at this link. Written 





These are usually commissioned but we are happy to 
consider and peer review unsolicited editorials. Please 
make clear the evidence base of each key statement: 
 
• Expert opinion; 
• Personal clinical experience; 
• Observational studies; 
• Trials; or 
• Systematic reviews. 
 
Please include a title page giving all authors’  names  
and corresponding details, as well as statements of 
competing interests and copyright/licence to publish. 
4.9 FILLERS AND ENDPIECES 
These are short articles that aim to entertain readers 
and make them think. Originally evolving to fill a gap in 
the print version of The BMJ, accepted submissions are 
now published online, and some are chosen to appear   
in print. 
 
We welcome submissions on topics such as: 
• A patient who changed my practice; 
• A memorable patient; 
• A paper that changed my practice; 
• The person who has most influenced me; 
• My most informative mistake; 





Examples of other articles  
The best way to get a feel for the 
different article types we publish is 
to look at a selection of our recently 
published content. Below you can 
find links to all content described 





Fillers and endpieces 
Word count 
Up to 800 words long. No more than 12 references 
 
4.6 PERSONAL VIEWS/BMJ OPINION 
These original, opinion based essays have a single 
author. The best personal view pieces make a strong, 
novel, and well argued point. They are also  often  
topical, insightful, and attention grabbing. We publish 
anonymous personal view articles only by special 
arrangement when it would be impossible for the article 
to appear with the author’s name. Accepted articles are 
all published online initially on BMJ Opinion, but may 
not be published in print. Please submit online at http:// 
submit.bmj.com. We cannot promise publication before 
the piece is submitted. 
 
We welcome  all  submissions  for  consideration   for 
our BMJ Opinion blog site. Writing should be clear, 
compelling, and appeal to our international readership. 
The best pieces make a single topical point. All opinion 
articles appear online. Those selected to appear in print 
receive a DOI and PubMed indexed. 
 
Word count 
600 words and 10 references (800 words for blogs) 
 
4.8 BMJ CAREERS 
If you have an idea for an article about doctors’ 
careers, please pitch it to us by emailing Tom Moberly 
(tmoberly@bmj.com). Send a few sentences explaining 
what you’d like to write about, how you’d like to cover 
the topic, and what you think readers would gain from 
the article you are proposing. If we like your idea we will 
contact you to discuss how we would like to proceed. 
Word count 
To   be   suitable   for   print,   Fillers   must   be   less than 
300 words.  Endpieces  are  quotations  of  no  more  
than    80    words    (often    fewer)    from    any   source. 
 
4.10 OBITUARIES 
We welcome obituaries for doctors with a connection 
to the UK within a year of their death. Please send your 
copy as a Word file to obituaries@bmj.com. We assume 
that material is sent exclusively to us, and we publish 
the full versions we receive on bmj.com. We produce 
the short obituaries in the print issue from these full 
versions; these usually appear with a time lag of several 
weeks. 
 
Obituaries include mandatory biographical details: 
the last position held, date of birth, place and year of 
qualification, postgraduate qualifications if applicable, 
and date and cause of  death.  Pictures  should  be  
sent as high—resolution images electronically or as 
photographs. We do not accept obituaries sent by post or 
handwritten obituaries. Please include a postal address 
if you want us to send one a copy of the relevant print 
issue to the families of the deceased (additional copies 
will have  to be purchased from    support@bmj.com). 
 
We generally  commission  the  full   page   obituaries  
for the print issue of The BMJ  from  professional 
writers: these are usually about doctors and are 
published no  more  than  three  months  after  death.  
We regret that we cannot provide individual progress 
updates.  NB:  Obituaries  are  not  indexed  in    PubMed. 
 
Word count 
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BMJ GUIDANCE FOR AUTHORS —  OTHER ARTICLE  TYPES  
ALL EDUCATION ARTICLES REQUIRE  
“What you need to know” box 
No more than three bullet points for practice articles and five for clinical updates encapsulating the specific take home 
messages from this article. 
“How patients were involved in the creation of this article” box 
Please include: Which patients were asked (e.g. patient advocates, networked patient communities and organisations, patients 
in your clinic etc). What they said (e.g. include more practical advice on how to inject insulin.) How you changed your article as a 
result (e.g. we included a box to address this.) 
“Education into practice” box. 
Include two to three bullet points about how a reader might at an individual or organisational level improve their practice (e.g. 
do you offer lifestyle advice to all patients with newly diagnosed hypertension?) 






The BMJ submission system  
You can submit articles using our 
system by visiting submit.bmj.com 
 
5.1 SUBMITTING AN ARTICLE 
Once you have read all of the above advice for your 
article type, and prepared your article, it's time to 
submit. Not all articles require submission through our 
submission system (some use a pitch form system), so 
please ensure you have taken note of this above before 
proceeding. 
 
At The BMJ, we use a system called ScholarOne to 
manage our submission processes. Essentially, 
ScholarOne will convert your manuscript to a PDF for 
the review process. Most common word processing 
formats are accepted for text and tables, although the 
system prefers Microsoft Word, and images should be 
submitted as GIF, TIFF, EPS, or JPEG  files. 
 
The system can also accept supplementary files (for 
example: videos, datasets, research protocols, and 
checklists  or  statements),  related  articles  published  
or available elsewhere, articles in press elsewhere, 
permission letters, etc. These are  files  that  normally  
do not appear with the print article, although they  
might accompany the final version of the paper online. 
Supplementary files are not converted to PDF but will be 




To access the system for the first time you will need to 
register here. Please  follow  the  "Register  here,"  link  
in the right hand grey column. You will be asked to 
complete three steps: 
 
• Name and email information; 
• Address information; 
• User ID and password; 
• Your job description, specialty and marketing 
preferences should also be filled in on this page. 
 
If you would like to be considered as a reviewer for The 
BMJ please also fill in your expertise terms. nyone can 
respond without a subscription to any article published 
on The BMJ by sending a rapid response. 
 
The submission process 
We offer a step by step guide to submission on our 
website, available on our Author Submission pages. 
 
Detailed help files are available throughout our online 
editorial office and can be used without stopping the 
submission process. If you experience serious problems 
please email The BMJ's editorial office at papersadmin@ 
bmj.com 
 
6.1 RAPID RESPONSES 
What are rapid responses? 
Anyone can respond without a subscription to any 
article published on The BMJ by sending a rapid 
response. 
 
Rapid responses are electronic letters to  the  editor.  
Our weekly letters are edited selections of posted rapid 
responses and are indexed in PubMed. Rapid responses 
are not indexed in PubMed but they have their own URL 
and are retrievable in an advanced search of thebmj.com 
in perpetuity. Thus a rapid response is published with its 
first appearance online. 
 
As an author, what should I know about rapid responses? 
The  corresponding  author  of  every  article  in  The  
BMJ receives an automated email when the paper is 
published online, and an automated reminder whenever 
a rapid response is posted to the article on thebmj.com. 
Given that authors have  an academic duty to respond   
to substantive criticism of their work, The BMJ expects 
authors to post their own rapid responses on bmj.com  
in reply to any such substantive comments, and editors 
may send reminders about this. 
 
How to send rapid responses? 
When you have found the article on thebmj.com that 
you would like to respond to, click on “Respond to this 
article” in the "Article Tools" section. 
 
Fill in the form, typing or cutting and pasting your rapid 
response into the larger box under “Compose your 
response”; using the smaller box for the response title. 
 
Accept the terms and conditions, and type the jumble of 
letters and numbers that you can see into the final box; 
these characters have  been generated automatically as  
a spam filter to determine whether you are human or 
machine. 
 
Click on 'Submit rapid response.' You  should then get     
a message on the screen thanking you for sending your 
response, as well as an automatic acknowledgement to 
your email address. These two measures confirm that 
your rapid response has arrived at thebmj.com to be 
considered for posting. 
 
Terms and conditions for rapid responses 
We have a wide list of terms and conditions for rapid 
responses, applicable for both authors and readers. 
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FURTHER INFORMATION FOR AUTHORS 
Although this document covers a large swathe of the article production and submission process at The BMJ, we offer a fully 
comprehensive guide for authors at our website, available at bmj.com/about—bmj/resources—authors 
Read about our publishing model in detail at bmj.com/about—bmj/publishing—model 
Read about our ethics and policies and our complaints procedure 
For any further queries, please contact papersadmin@bmj.com 
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